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ABSTRACT

The present invention is directed towards an artificial RNA
nano structure comprising multiple external strands of RNA,
each external strand comprising about 40-50 nucleotides;
one internal strand of RNA comprising more than about 50
nucleotides; the internal strands and external strands
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Such nanostructure can be provided in a composition
together with an adjuvant for use in inducing the production
of high affinity neutralizing antibodies or inhibitory antibodies, inducing the production of cytokines, inducing an
immune response in a subject, or a combination thereof.
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HG.56

l\21. Cot,
RNi4,
.,
* 5} -UCCAUGACG UUCCUGACGU UUUUUUUACA
GUCGUAU UGC AU UCCGA-3' 46 SEQ ID NO: 16
• DNA : TAA TAC GAC TCA CTATA TCC ATG ACG
TTC CTG ACG TTT TTT T TAC AGT CGT ATT GCA
TTC CGA 63nt sEQroNo: 2s
• 5' Pdmer: TAA TAC GAC TCA CTATA TCC ATG
ACG TTC CTG ACG TTT SEQ ID NO: 26
~ !f Primer: TCGGAATGCA ATACGACTGT
AAAAAAAACG TCAGGAA SEQ ID NO: 27
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5'-UCCAUGACGU UCCUGACGUU UUUUUCCAUA
CCGCCAUUUC CAACUA-3} 46n __ sEQIDNo: rn

DNA: TAA TAC GAC TCA CTATA TCC ATG ACG TTC
CTG ACG TTT TTT T CCA TAC CGC CAT TIC CAA
CTA 63n1 sEQ 10 No: 2s

~

5' Primer: TAA TAC GAC TCA CTATA TCC ATG ACG
TIC CTG ACG TTT SEQ ID NO: 29

~

31 Primer: TAGTTGGAAA TGGCGGTATG
GAAAAAAACG TCAGGAA SEQ ID NO: 30
FIG. 58
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#

51 -UCCAUGACGU UCCUGACGUU UUUUUAAGCA
CAUGCGAUGU UUAACU-3" 46n sEQIDNo:20
DNA: TAA TAC GAC TCA CTATA TCC ATG ACG TTC
CTG ACG TTT TIT T AAG CAC ATG CGA TGT TTA
ACT 63nt sEQ10No:J1

5' Primer: TAA TAC GAC TCA CTATA TCC ATG ACG
TIC CTG ACG TTT SEQ ID NO: 32
3' Primer: AGTTAAACAT CGCATGTGCT

TAAAAAAACG TCAGGAA
FIG. 59
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RNA-BASED COMPOSITIONS AND
ADJUVANTS FOR PROPHYLACTIC AND
THERAPEUTIC TREATMENT

excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
The presently-disclosed subject matter comprises RNA
that can be used as a construction material, immunostimulatory agent, or a combination thereof for the development
of new nanovaccines and adjuvants for disease prevention
and treatment.
The presently-disclosed subject matter comprises a composition which is comprised of an RNA-oligonucleotide,
which can be single-stranded or double stranded, and an
immunostimulatory motif.
In some embodiments, the RNA-oligonucleotide comprises a chemical modification. In some preferred embodiments, the chemical modification is selected from 2'Fluoro,
2'Amine, and 2'O-Methyl. In some embodiments, the RNAoligonucleotide is about 8-50 bases in length. In some
embodiments, the RNA-oligonucleotide is partially double
stranded, for example containing a hair-pin.
In some embodiments, the immunostimulatory motif is
immunostimulatory RNA or a CpG oligodeoxyribonucleotide. In some embodiments, the immunostimulatory motif
is conjugated to the RNA-oligonucleotide. In some embodiments the immunostimulatory motif is oligodeoxyribonucleotide. In some embodiments, the composition is provided as
an adjuvant.
The presently-disclosed subject matter comprises an artificial RNA nanostructure comprising multiple external
strands and one internal strand, wherein the external strands
and internal strand self-assemble to form a nanostructure. In
some embodiments, the multiple external strands can, for
example, be 3, 4, or 5 strands. In some embodiments, the
external strands comprise about 48 nucleotides; and in some
preferred embodiments, the nanostructure comprises a
pRNA3WJ motif at each vertex. In some embodiments, the
external strands comprise more than 48 nucleotides. In some
embodiments, the external strands comprise less than 48
nucleotides. In some embodiments, the external strands
comprise about 10, about 20, about 30, about 40, about 50,
about 60, about 70, about 80, about 90, about 100 nucleotides.
In some embodiments the artificial RNA nanostructure
comprises a triangle and has a stretched intrahelical angle
between about Hl and H2. In other embodiments, the
nanostructure comprises a square and has a stretched intrahelical angle between about Hl and H2. In other embodiments, nanostructure comprises a pentagon and has a
stretched intrahelical angle between about Hl and H2. In
some embodiments, the RNA nanostructure comprises an
RNA triangle, RNA square, RNA pentagon, RNA hexagon,
RNA three-way junction, and RNA four-way junction. In
some embodiments, the RNA nanostructure is derived from
a 3WJ motif. In some embodiments, the RNAnanostructure
comprises a stretched intrahelical angle between about Hl
and H2, as exemplified in FIG. 1.
In some embodiments, the subject matter relates to a
composition comprising an RNA nanostructure that comprises an adjuvant, an antigen, and/or a targeting ligand. In
some embodiments, the composition induces an immune
response. In some embodiments, the immune response
increases cytokine at least ten fold as compared to the
adjuvant, the antigen, and/or the targeting ligand provided
independently of the RNA nano structure. In some embodiments, the adjuvant comprises a composition comprising an
RNA-oligonucleotide and an immunostimulatory motif. In
some embodiments, the RNA-oligonucleotide and immunostimulatory motif are incorporated into the RNA nanoparticle by the RNA-oligonucleotide being covalently bonded

RELATED APPLICATIONS

5

This application is a continuation-in-part of PCT application No. PCT/US2015/036798, filed Jun. 19, 2015, which
claims priority of U.S. Provisional Patent Application No.
62/014,503, filed Jun. 19, 2014, and the entire disclosures of
which are hereby incorporated by reference in their entireties.
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GOVERNMENT INTEREST
This invention was made with govermnent support under
EB003730, EB 012135, and CA 151648 awarded by the
National Institutes of Health. The govermnent has certain
rights in the invention.
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SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Feb. 23, 2017, is named 2935720-000002
SL.txt and is 25,100 bytes in size.

25

TECHNICAL FIELD
30

The presently-disclosed subject matter relates to RNAbased compositions, including immunostimulatory RNAcontaining compositions and RNA nanoparticle-containing
compositions, methods of making the compositions, and use
of RNA-based adjuvants for prophylactic and therapeutic
treatment.

35

INTRODUCTION
Cancer and infectious diseases such as influenza and
human immunodeficiency virus infection/acquired immunodeficiency syndrome (HIV/AIDS) are still a huge threat to
public health world-wide. Prophylactic and treatment vaccines could offer promising opportunities for controlling
these diseases. However, despite tens of years of extensive
research, such vaccines are still far away from completely
controlling these diseases due to either low effectiveness or
safety issues. New strategies and approaches in designing
and developing new vaccines and adjuvants targeting these
diseases are urgently needed.
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SUMMARY
The presently-disclosed subject matter meets some or all
of the needs as described herein, as will become evident to
those of ordinary skill in the art after a study of information
as described herein.
This S=ary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
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to an RNA strand of the RNA nanoparticle. Non-limiting
examples of the bond between RNA-oligonucleotide and the
RNA strand of the RNA nanoparticle is ionic bond or
hydrogen bond. In some embodiments, the RNA-oligonucleotide and immunostimulatory motif are incorporated
into the RNA nanoparticle by base pairing between the
RNA-oligonucleotide and the RNA nanoparticle. In some
embodiments, the adjuvant comprises an immunostimulatory RNA (isRNA), and in some embodiments the adjuvant
comprises a CpG oligodeoxyribonucleotide. In some
embodiments, the adjuvant comprises isRNA that is about 8
to about 50 bases in length. In some embodiments, the
adjuvant comprises isRNA that is less than 8 bases in length.
In some embodiments, the adjuvant comprises isRNA that is
more than 50 bases in length. In some embodiments, the
adjuvant comprises isRNA that is about 1, about 2, about 3,
about 4, about 5, about 6, about 7, about 8, about 9, about
10, about 20, about 30, about 40, about 50, about 60, about
70, about 80, about 90, about 100 bases in length. In some
embodiments, the adjuvant is CpG RNA. In some embodiments, the adjuvant is covalently bonded to an RNA strand
of the RNA nanoparticle. In other embodiments, the adjuvant is incorporated into the RNA nanoparticle by base
pairing.
Embodiments as described herein comprise one or more
of the sequences of SEQ ID NOS: 16-24. In one embodiment, the oligonucleotide has at least 60%, at least 65%, at
least 70%, at least 80%, at least 85%, at least 90%, at least
91 %, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, at least 99%, or
100% identity to a nucleic acid sequence comprising SEQ
ID NOS: 16-24. In one embodiment, the oligonucleotide has
at least 60%, at least 65%, at least 70%, at least 80%, at least
85%, at least 90%, at least 91 %, at least 92%, at least 93%,
at least 94%, at least 95%, at least 96%, at least 97%, at least
98%, at least 99%, or 100% similarity to a nucleic acid
sequence comprising SEQ ID NOS: 16-24.
In some embodiments, the RNA nanostructure comprises
an antigen. In some embodiments, the antigen is derived
from a bacteria, virus, or cell. In some embodiments, the
antigen binds to a neutralizing antibody or an inhibitory
antibody. In some embodiments, the antigen comprises a
neutralizing epitope. In some embodiments, the antigen
comprises B-cell epitope, T-cell epitope, T-helper epitope,
epitopes derived from PG120, gp41 epitopes, glycans, peptides, T-helper peptides, streptavidin, or a combination
thereof.
In some embodiments, the RNA nanostructure comprises
a targeting ligand. In some embodiments, the targeting
ligand comprises an aptamer, a cell surface marker, folate,
siRNA, shRNA, or a combination thereof. In some embodiments, the aptamer binds to an HIV epitope. In other
embodiments, the cell surface marker comprises a macrophage or lymphocyte. In some embodiments, the targeting
ligand targets B cells, T cells, dendritic cells, macrophages,
cancer cells, or a combination thereof. In some embodiments, there are more than one targeting ligand. In some
embodiments, the targeting ligands are the same. In other
embodiments, the targeting ligands are not all the same.
Embodiments as described herein comprise a method of
inducing an immune response in a subject, comprising
administering to the subject an effective amount of the
compositions of the present invention. In some embodiments, the method comprises administering an RNA-oligonucleotide and an immunostimulatory motif. In some
embodiments, the method comprises administering a com-

position comprising an RNA nanostructure and an adjuvant,
an antigen, and/or a targeting ligand.
Embodiments as described herein comprise a method of
inducing the production of cytokines. In some embodiments,
the cytokines comprise TNF-alpha, IL-6, IL-12, or a combination thereof. In some embodiments, the method comprises administering an RNA-oligonucleotide and an immunostimulatory motif. In some embodiments, the production
of cytokines is increased at least ten fold as compared to the
immunostimulatory motif provided independently of the
RNA-oligonucleotide.
In some embodiments, the method comprises administering a composition comprising an RNA nano structure and an
adjuvant, an antigen, a targeting ligand, or a combination of
the adjuvant, ligand, or targeting ligand. In some embodiments, the induction of the production of cytokines is
increased at least ten fold as compared to the adjuvant, the
antigen, and/or the targeting ligand provided independently
of the RNA nanostructure.
In some embodiments, administering a composition as
described herein to a subject induces the production of high
affinity neutralizing antibodies or inhibitory antibodies. In
some embodiments, the subject has or is at risk of having a
pathological condition. In some embodiments, the pathological condition comprises cancer, human immunodeficiency virus (HIV), influenza, drug and substance abuse, or
a combination thereof.
In some embodiments, embodiments as described herein
are used for the manufacture of a medicament useful for the
treatment of a pathological condition in a subject. In some
embodiments, the medicament is used prophylactically.
Embodiments as described herein also provide methods of
making an RNA nanostructure. In some embodiments, the
method of making an RNA nano structure comprises mixing
equimolar concentrations of a multiple of external RNA
strands, and one internal RNA strand to make a mixture,
annealing the mixture, and cooling the mixture slowly. In
some embodiments, the mixture is cooled at about 1° C. per
minute. In some embodiments, the mixtures is cooled faster
or slower than about 1° C. per minute. In some embodiments, the mixture is cooled from about 80° C. to about 4 °
C. In some embodiments, the mixture is cooled to a temperature greater than 80° C. In some embodiments, the
mixture is cooled to a temperature less than 80° C. In some
embodiments, the mixture is cooled to about 1° C., about 2°
C., about 3° C., about 4° C., about 5° C., about 6° C., about
7° C., about 8° C., about 9° C., about 10° C., about 20° C.,
about 30° C., about 40° C., about 50° C., about 60° C., or
about 70° C. In some embodiments, the mixture is annealed
for about one hour. In some embodiments, the mixture is
annealed for more than one hour. In some embodiments, the
mixture is annealed for less than one hour. In some embodiments, the mixture is annealed for up to about 10, about 20,
about 30, about 40, or about 50 minutes. In some embodiments, the mixture is annealed for up to about 1, about 2,
about3,about4,about5,about6,about 10,about 12,about
18, or about 24 hours. In some embodiments, the method
comprises modifying one or more of the external strands to
comprise at least one antigen, at least one adjuvant, at least
one targeting ligand, or a combination thereof. In some
embodiments, there are optionally 3, 4, or 5 external strands.
In some embodiments, the external strands comprise about
48 nucleotides. In some embodiments, the external strands
comprise more than 48 nucleotides. In some embodiments,
the external strands comprise less than 48 nucleotides. In
some embodiments, the external strands comprise about 10,
about 20, about 30, about 40, about 50, about 60, about 70,
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about 80, about 90, about 100 nucleotides. In some embodiments, the nanostructure produces by the method comprises
a pRNA 3WJ motif at each vertex. In some methods, the
nanostructure shape comprises a triangle, square and pentagon. In some embodiments, the shapes produced by the
method have a stretched intrahelical angle between about Hl
and about H2.
Embodiments as described herein comprise an RNAoligonucleotide and an immunostimulatory motif. In
embodiments, the RNA oligonucleotide can be singlestranded, double stranded, or partially double stranded. In
embodiments, the RNA-oligonucleotide comprises a chemical modification, examples of which comprise 2'Fluoro,
2'Amine, and 2'O-Methyl. In embodiments, the RNA oligonucleotide comprises about 8 to about 50 bases in length.
Embodiments as described herein comprise an immunostimulatory motif. In embodiments, the immunostimulatory
motif comprises an immunostimulatory RNA (isRNA), and
a CpG oligodeoxyribonucleotide. In embodiments, the
immunostimulatory motif can be conjugated to the RNAoligonucleotide. For example, the immunostimulatory motif
is CpG oligodeoxyribonucleotide conjugated to the RNAoligonucleotide. For example, the isRNA is CpG RNA
conjugated to the RNA-oligonucleotide. Embodiments as
described herein can be provided as an adjuvant.
Embodiments as described herein comprise the oligonucleotide sequence of A21 CpG RNA (SEQ ID NO: 16),
B21 CpG RNA (SEQ ID NO: 18), and C21 CpG RNA (SEQ
ID NO: 20). Embodiments as described herein comprise one
or more of the sequences of SEQ ID NOs 16-21. In one
embodiment, the oligonucleotide has at least 60%, at least
65%, at least 70%, at least 80%, at least 85%, at least 90%,
at least 91 %, at least 92%, at least 93%, at least 94%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99%,
or 100% identity to a nucleic acid sequence comprising SEQ
ID Nos 16-21. In one embodiment, the oligonucleotide has
at least 60%, at least 65%, at least 70%, at least 80%, at least
85%, at least 90%, at least 91 %, at least 92%, at least 93%,
at least 94%, at least 95%, at least 96%, at least 97%, at least
98%, at least 99%, or 100% similarity to a nucleic acid
sequence comprising SEQ ID Nos 16-21.
Embodiments as described herein comprise an artificial
RNA nanostructure comprising three, four, or five external
strands of RNA. In embodiments, each external strand
comprises about 40 to about 50 nucleotides; one internal
strand of RNA, including more than about 50 nucleotides,
the internal strands and external strands assembled to form
a triangle nanostructure, a square nanostructure, or a polygon nanostructure; and a pRNA three-way junction (3WJ)
motif at each vertex of the nanostructure.
In embodiments, the nanostructure comprises a triangle.
In embodiments, the triangle has a stretched intrahelical
angle between about Hl and about H2. In embodiments, the
angle comprises about 60°. In embodiments, the angle
comprises greater than 60°. In other embodiments, the angle
comprises less than 60°.
In embodiments, the nanostructure comprises a square. In
embodiments, the square has a stretched intrahelical angle
between about Hl and about H2. In some embodiments, the
angle comprises about 90°. In embodiments, the angle
comprises greater than 90°. In other embodiments, the angle
comprises less than 90°.
In embodiments, the nanostructure comprises a pentagon.
In embodiments, the pentagon has a stretched intrahelical
angle between about Hl and about H2. In some embodiments, the angle comprises about 100°. In embodiments, the

angle comprises greater than 108°. In other embodiments,
the angle comprises less than 108°.
Embodiments as described herein comprise one or more
of the sequences of SEQ ID NOs 1-4. In one embodiment,
the oligonucleotide has at least 60%, at least 65%, at least
70%, at least 80%, at least 85%, at least 90%, at least 91 %,
at least 92%, at least 93%, at least 94%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99%, or 100%
identity to a nucleic acid sequence comprising SEQ ID Nos
1-4. In one embodiment, the oligonucleotide has at least
60%, at least 65%, at least 70%, at least 80%, at least 85%,
at least 90%, at least 91 %, at least 92%, at least 93%, at least
94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% similarity to a nucleic acid sequence
comprising SEQ ID Nos 1-4.
Embodiments as described herein comprise one or more
of the sequences of SEQ ID NOs 5-9. In one embodiment,
the oligonucleotide has at least 60%, at least 65%, at least
70%, at least 80%, at least 85%, at least 90%, at least 91 %,
at least 92%, at least 93%, at least 94%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99%, or 100%
identity to a nucleic acid sequence comprising SEQ ID Nos
5-9. In one embodiment, the oligonucleotide has at least
60%, at least 65%, at least 70%, at least 80%, at least 85%,
at least 90%, at least 91 %, at least 92%, at least 93%, at least
94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% similarity to a nucleic acid sequence
comprising SEQ ID Nos 5-9.
Embodiments as described herein comprise one or more
of the sequences of SEQ ID NOs 10-15. In one embodiment,
the oligonucleotide has at least 60%, at least 65%, at least
70%, at least 80%, at least 85%, at least 90%, at least 91 %,
at least 92%, at least 93%, at least 94%, at least 95%, at least
96%, at least 97%, at least 98%, at least 99%, or 100%
identity to a nucleic acid sequence comprising SEQ ID Nos
10-15. In one embodiment, the oligonucleotide has at least
60%, at least 65%, at least 70%, at least 80%, at least 85%,
at least 90%, at least 91 %, at least 92%, at least 93%, at least
94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% similarity to a nucleic acid sequence
comprising SEQ ID Nos 10-15.
Embodiments as described herein comprise one or more
immunostimulatory motifs as described herein. For
example, such motifs comprise one or more immunostimulatory RNAs (isRNA) or CpG motifs.
Embodiments as described herein comprise an RNA
nanostructure as described herein, an adjuvant, an antigen, a
targeting ligand, or a combination thereof. In embodiments,
the RNA nanostructure comprises an RNA triangle, RNA
square, RNA pentagon, RNA hexagon, RNA three-way
junction, RNA four-way junction, or any combination
thereof. Embodiments as described herein can be derived
from a 3JW motif. In embodiments, the RNA nanostructure
contains a stretched intrahelical angle between Hl and H2,
as described herein.
In embodiments, the adjuvant comprises an immunostimulatory RNA (isRNA) and a CpG oligodeoxyribonucleotide (CpG). In embodiments, the isRNA comprises an
oligonucleotide comprising about 8 to about 50 bases in
length.
In embodiments, the isRNA is incorporated into the RNA
nanoparticle by being covalently bonded to an RNA strand
of the RNA nanoparticle. In embodiments, the isRNA comprises CpG RNA. In embodiments, the CpG RNA comprises
A21 CpG RNA (SEQ ID NO: 16), B21 CpG RNA (SEQ ID
NO: 18), and C21 CpG RNA (SEQ ID NO: 20), as described
herein.
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In embodiments, the isRNA is incorporated into the RNA
nanoparticle by base pairing. In embodiments, the isRNA
comprises a CpG RNA. In embodiments, the CpG RNA
comprises A21 CpG RNA (SEQ ID NO: 16), B21 CpG RNA
(SEQ ID NO: 18), and C21 CpG RNA (SEQ ID NO: 20), as
described herein.
In embodiments, an adjuvant refers to a composition as
described herein given in combination with an RNA nanostructure to enhance its immunogenicity.
In embodiments, the RNA-oligonucleotide and immunostimulatory motif are incorporated into the RNA nanoparticle by base pairing between the RNA-oligonucleotide and
the RNA nanoparticle.
In embodiments, the RNA-oligonucleotide and immunostimulatory motif are incorporated into the RNA nanoparticle by the RNA-oligonucleotide being covalently bonded
to an RNA strand of the RNA nanoparticle.
In embodiments, the antigen comprises at least one antigen derived from a bacteria, virus, cell, a combination
thereof, or a portion thereof.
In embodiments, the antigen comprises at least one antigen that binds to a neutralizing antibody, an inhibitory
antibody, a combination thereof, or a portion thereof.
In embodiments, the antigen comprises at least one neutralizing epitope.
In embodiments, the antigen comprises B-cell epitope,
T-cell epitope, T-helper epitope, epitopes derived from
PG120, gp41 epitopes, glycans, peptides, T-helperpeptides,
streptavidin, or a combination thereof.
In embodiments, the targeting ligand comprises an
aptamer, a cell surface marker, folate, siRNA, shRNA, or a
combination thereof. In embodiments, the aptamer binds to
an HIV epitope. In embodiments, the cell surface marker is
a macrophage or a lymphocyte. In embodiments, the targeting ligand targets B cells, T cells, dendritic cells, macrophages, and/or cancer cells.
Embodiments as described herein comprise one or more
targeting ligands. Embodiments as described herein comprise at least two targeting ligands. In embodiments, the
targeting ligands are the same. In other embodiments, the
targeting ligands are not all the same. In other embodiments,
the targeting ligands are different.
Embodiments as described herein induce an immune
response in a subject. In embodiments, the immune response
increases cytokines at least about one fold, about two fold,
about three fold, about four fold, about five fold, about six
fold, about seven fold, about eight fold, about nine fold,
about ten fold, about fifteen fold, about twenty fold, about
thirty fold, about forty fold, about fifty fold as compared to
the adjuvant, the antigen, and/or the targeting ligand provided independently of the RNA nanostructure.
Embodiments as described herein comprise a method of
inducing an immune response in a subject comprising
administering to the subject an effective amount of an
embodiment as described herein.
Embodiments as described herein comprise a method of
inducing the production of cytokines comprising administering to a subject an effective amount of an embodiment as
described herein. In embodiments, the inducing the production of cytokines is increased at least about one fold, about
two fold, about three fold, about four fold, about five fold,
about six fold, about seven fold, about eight fold, about nine
fold, about ten fold, about fifteen fold, about twenty fold,
about thirty fold, about forty fold, about fifty fold as compared to the immunostimulatory motif provided independently of the RNA-oligonucleotide.

In embodiments, the subject has or is at risk of having a
pathological condition. In embodiments, the subject has
been diagnosed with a pathological condition. In embodiments, the pathological condition comprises cancer, human
immunodeficiency virus (HIV), influenza, drug and substance abuse, or a combination thereof.
Embodiments as described herein comprise a method of
inducing the production of cytokines. In embodiments, the
method comprises administering to the subject an effective
amount of an embodiment as described herein. In embodiments, the inducing the production of cytokines is increased
at least about one fold, about two fold, about three fold,
about four fold, about five fold, about six fold, about seven
fold, about eight fold, about nine fold, about ten fold, about
fifteen fold, about twenty fold, about thirty fold, about forty
fold, about fifty fold as compared to the adjuvant, the
antigen, and/or the targeting ligand provided independently
of the RNA nanostructure. In embodiments, the cytokines
comprise TNF-alpha, IL-6, IL-12, or a combination thereof.
In embodiments, the subject has or is at risk of having a
pathological condition. In embodiments, the subject has
been diagnosed with a pathological condition. In embodiments, the pathological condition comprises cancer, human
immunodeficiency virus (HIV), influenza, drug and substance abuse, or a combination thereof.
Embodiments as described herein comprise a method of
inducing the production of high affinity neutralizing antibodies or inhibitory antibodies. In embodiments, the method
comprises administering embodiments as described herein
to a subject having a pathological condition. In embodiments, the pathological condition comprises cancer, human
immunodeficiency virus (HIV), influenza, drug and substance abuse, or a combination thereof.
Embodiments as described herein comprise the use of
embodiments as described herein for the manufacture of a
medicament useful for the treatment of a pathological condition in a subject. In embodiments, the pathological condition comprises cancer, human immunodeficiency virus
(HIV), influenza, drug and substance abuse, or a combination thereof.
Embodiments as described herein comprise a composition
as described herein for use in the prophylactic or therapeutic
treatment of a pathological condition. In embodiments, the
pathological condition comprises cancer, human immunodeficiency virus (HIV), influenza, drug and substance abuse,
or a combination thereof.
Embodiments as described herein comprise a method of
making an RNAnanostructure. In embodiments, the method
comprises mixing a multiple of external RNA strands, and
one internal RNA strand to make a mixture; annealing the
mixture for one hour in a thermocycler; cooling the mixture
at about 1° C. per minute from about 80° C. to about 4 ° C.
In embodiments, equimolar concentrations of a multiple of
external RNA strands, and one internal RNA strand can be
mixed. In embodiments, the mixture can be annealed for 1,
5, 10, 20, 30, 40, 50, 60, 70, 80, 90 minutes. In embodiments, the mixture can be cooled to 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 20, 30, 40, 50, 60, 70° C. In embodiments, the mixture
can be cooled at about 1, about 2, about 3, about 4, about 5,
about 6, about 7, about 8, about 9, about 10° C. per minute.
In embodiments, the method can further comprise modifying one or more of the external strands to contain an antigen,
adjuvant, targeting ligand, or combination thereof. In
embodiments, the external strands comprise 1, 2, 3, 4, 5, 6,
7, 8, 9, 10 strands. In embodiments, the external strands
comprise 10, 20, 30, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49,
50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 nucleotides. In
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embodiments, the nanostructure comprises a pRNA 3WJ
motif at each vertex. In embodiments, the nano structure has
a shape comprising a triangle, square and pentagon. In
embodiments, the shape comprises a stretched intrahelical
angle between Hl and H2.
Embodiments as described herein can comprise one or
more of SEQ ID. NO 1, SEQ ID. NO 2, SEQ ID. NO 3, SEQ
ID. NO 4, SEQ ID. NO 5, SEQ ID. NO 6, SEQ ID. NO 7,
SEQ ID. NO 8, SEQ ID. NO 9, SEQ ID. NO 10, SEQ ID.
NO 11, SEQ ID. NO 12, SEQ ID. NO 13, SEQ ID. NO 14,
SEQ ID. NO 15, SEQ ID. NO 16, SEQ ID. NO 17, SEQ ID.
NO 18, SEQ ID. NO 19, SEQ ID. NO 20, SEQ ID. NO 21,
SEQ ID. NO 22, SEQ ID. NO 23, SEQ ID. NO 24, SEQ ID.
NO 25, SEQ ID. NO 26, SEQ ID. NO 27, SEQ ID. NO 28,
SEQ ID. NO 29, SEQ ID. NO 30, SEQ ID. NO 31, SEQ ID.
NO 32, SEQ ID. NO 33, or any combination thereof. In one
embodiment, the oligonucleotide has at least 60%, at least
65%, at least 70%, at least 80%, at least 85%, at least 90%,
at least 91 %, at least 92%, at least 93%, at least 94%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99%,
or 100% identity to a nucleic acid sequence comprising SEQ
ID Nos 1-33. In one embodiment, the oligonucleotide has at
least 60%, at least 65%, at least 70%, at least 80%, at least
85%, at least 90%, at least 91 %, at least 92%, at least 93%,
at least 94%, at least 95%, at least 96%, at least 97%, at least
98%, at least 99%, or 100% similarity to a nucleic acid
sequence comprising SEQ ID Nos 1-33.

FIGS. 4A and 4B shows a comparison of polygon stabilities. (A) Melting temperatures of triangle, square and
pentagon measured by 7% perpendicular TGGE and (B)
boiling resistance assay in absence and presence of 8 M
urea. Calculated percentage of recovery for polygons after
boiling is shown below each gel with error bars calculated
from several independent experiments.
FIGS. SA-SD shows the effect of cytokine induction in
macrophage-like RAW264.7 cells and mice by RNA-CpG
polygons. Induction of (A) TNF-a and (B) IL-6 cytokines by
50 nM RNA polygons-CpG. (C) Dependences of TNF-a
induction with the number of CpGs per RNA polygon. The
error bars represent standard deviation from at least three
independent experiments. (D) Immunostimulatory activity
by triangle-CpG nanoparticle in animal model. The error
bars represent standard deviations of two independent measurements of the cytokine levels from serum aliquots of the
tested mouse.
FIGS. 6A and 6B shows a comparison of RNA polygonCpG complexes binding to the cells. (A) The plot represents
the summary of the flow cytometry data showing each RNA
nanoparticle-CpG adjuvants binding to the cell in a dosedependent manner. (B) Confocal images showing the binding comparison of the triangle-CpG and CpG to the
RAW624.7 cells by colocalization of nucleus (blue), actin or
cytoplasm (green) and Cy-3-labeled CpGs (red) signals.
FIGS. 7A-7D shows RNA polygons dissociation constant
determination at equilibrium state. These are 7% native
PAGE titration data for formation of triangle (a), square (b),
and pentagon (c) polygons. Below, the gels is the plot used
to determine the equilibrium concentration for each polygon
which were then used to calculate the apparent dissociation
constant.
FIGS. SA-SC shows sequences and secondary structures
of RNA polygons. RNA polygons and quantified assembly
yields for triangle (a), square (b) and pentagon (c). FIG. SA
discloses regions ArRrDrRI as SEQ ID NOS 37-40, respectively. FIG. SB discloses regions AsQR-EsQR as SEQ ID
NOS 41-45, respectively. FIG. SC discloses regions APENrFPENT as SEQ ID NOS 46-51, respectively.
FIG. 9A-9C shows RNA polygons population on mica
surface AFM images of RNA polygons and population
distribution of RNA triangle (a), square (b ), and pentagon (c)
polygons in 0.5 mm2 area of AFM mica surface. Error
represents counts from several independent images.
FIGS. lOA and lOB shows secondary structure of triangle-CpG nanoparticle and characterization. (a) 2D structure of RNA triangle harboring 3 CpG adjuvants. Note:
Arrows indicate to base pairs that have been deleted in RNA
triangle nanoparticle use for animal confocal microscope,
and cytotoxicity studies. (b) This is 4% agarose gel showing
assembly of RNA triangle nanoscaffold with CpG adjuvants.
FIG. lOC shows (c) DLS characterization of the triangle3CpG complex showing apparent hydrodynamic diameter of
around 14 nm. The error represents standard deviation from
several independent measurements.
FIG. 11 shows the secondary structure of a square-CpG
nanoparticle and characterization. (a) 2D structure of RNA
square harboring 4 CpG adjuvants. Figure discloses regions
AsQR-EsQR as SEQ ID NOS 59 and 60, 61 and 62, 63 and
64, 65, and 66, respectively. (b) This is 4% agarose gel
showing assembly of RNA square nanoscaffold with CpG
adjuvants. (c) DLS characterization of the square-4CpG
complex showing apparent hydrodynamic diameter of
around 15 nm. The error represents standard deviation from
several independent measurements.
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The new features of embodiments as described herein are
set forth with particularity in the appended claims. The
drawings were originally published in color, incorporated by
reference in their entireties (Emil F. Khisamutdinov, et. al.,
Enhancing immunomodulation on innate immunity by shape
transition among RNA triangle, square and pentagon
nanovehicles, Nucleic Acids Res. 2014 Sep. 2; 42(15):
9996-10004.). The black and white drawing of the instant
application correspond to the color ones published. A better
understanding of the features and advantages of the present
invention will be obtained by reference to the following
detailed description that sets forth illustrative embodiments,
in which the principles of the invention are used, and the
accompanying drawings of which:
FIGS. lA and lB shows details of the structural features
of the pRNA 3WJ motif. (A) Secondary structure of 3WJ
motif with base pairs annotated using Leontis-Westhof
nomen-clature. Figure discloses SEQ ID NOS 34-36,
respectively, in order of appearance. (B) Tertiary structure of
the 3WJ motif with indication of the LAOB-60° angle
formed between Hl and H2. The LAOB Angle corresponds
to inner angles of polygons.
FIGS. 2A-2C shows the design of RNA nanostructure
polygons and assembly properties. (A) 3D modeled structures of polygons with 3WJ motif located at vertices, inner
angle corresponds to LAOB 60°. (B) The increasing length
of the internal strand stretches the 3WJ LAOB at which the
nanoparticles assemble, along with increasing number of
external 'short' strands. FIG. 2 (C) Assembly properties of
polygons evaluated on 7% native PAGEs. Asterisks '*'
indicate the Cy5 labeled strands utilized on each type of
polygon assembly.
FIG. 3 shows structural characterization of polygons. (A)
Atomic Force Microscopy (AFM) images of triangular,
square and pentagonal nanoparticles derived from the pRNA
3WJ motif. (B) Polygons size distribution histogram
obtained via dynamic light scattering.
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FIG. 12 shows the secondary structure of a pentagon-CpG
nanoparticle and characterization. (a) 2D structure of RNA
pentagon harboring 5 CpG adjuvants. Figure discloses
regions APENrFPENT as SEQ ID NOS 67 and 68, 69 and 70,
71 and 72, 73 and 74, 75 and 76, and 77, respectively. (b)
This is 4% agarose gel showing assembly of RNA pentagon
nanoscaffold with CpG adjuvants. (c) DLS characterization
of the pentagon-5CpG complex showing apparent hydrodynamic diameter of around 16 nm. The error represents
standard deviation from several independent measurements.
FIG. 13 shows the effect of RNA-CpG adjuvants on
RAW264.7 cell viability. The cells were incubated with
different concentrations of RNA polygons only, RNA polygons-CpG complexes, and free CpG.
FIG. 14 shows the binding effect of RNA polygons
harboring CpG adjuvants to RAW264. 7 cells. Concentration
dependent binding of (a) triangle-3CpGs, (b) square-4CpGs,
and (c) pentagon-5CpGs nanoparticles.
FIG. 15 shows the results of a serum stability assay of
RNA polygons coupled with CpGs motifs. Preassembled
complexes (1 µM) of RNA triangle, square and pentagon
(2'-F modified) harboring DNA CpG were incubated in
RPMI-1640 medium containing 10% fetal bovine serum
(Sigma). Aliquots (10 µL) were taken at Ohr, 1 hr, 3 hr, 6 hr,
8 hr and 16 hr time points after incubation at 37° C.,
followed by analysis using 6% native PAGE gel.
FIG. 16 shows thermodynamically stable RNA nanoparticles for efficient delivery of immunostimulatory CpG oligonucleotides, RNA or antigen to immune cells,
FIG. 17 shows RNA and DNA sequence for triangle3CpGs (SEQ ID NOS 78-85, 17, 19, and 21, respectively, in
order of appearance)
FIG. 18 shows CpG only, a nanostructure RNA triangle
only, and a RNA nano structure triangle with optionally one,
two and three CpGs.
FIG. 19 shows thermodynamically stable RNA three-way
junction (3WJ) for efficient delivery of immunostimulatory
CpG oligonucleotides, RNA or antigen to immune cells.
Figure discloses SEQ ID NOS 86-88, respectively, in order
of appearance.
FIG. 20 shows a bowtie-like RNA nanoparticle triangle
dimer for delivery of 4CpG. The size of the nanoparticle is
twice as triangle (about 20 nmx15 nm).
FIG. 21 shows RNA triangle, square and pentagon nanoparticles harboring different numbers of CpGs and Cy3labeled DNAs
FIG. 22 shows an RNA nanoparticle for anticancer vaccine or immunotherapy
FIG. 23 shows a 3WJ nanovaccine containing CpG-ODN
adjuvant and antitumor antigen and a 4WJ nanovaccine
containing CpG-ODN adjuvant and antitumor antigen
FIG. 24 shows a Triangle RNA nanostructure harboring
CpG-G ODN and siRNA.
FIG. 25 shows the assemblies of RNA nanostructure
triangles harboring CpG oligonucleotides.
FIG. 26 shows AFM images of RNA nanostructure triangles harboring three CpGs.
FIG. 27 shows AFM images of RNA nanostructure triangles harboring three CpGs.
FIG. 28 shows AFM images of RNA nanostructure triangles harboring three CpGs.
FIG. 29 shows AFM images of RNA nanostructure triangles harboring three CpGs.
FIG. 30 shows AFM images of RNA nanostructure triangles harboring three CpGs.
FIG. 31 shows detailed AFM images of RNA nanostructure triangles harboring three CpGs and a scheme of the CpG

harboring RNA triangle. Triangle with 2 CpG ODN can be
successfully purified and imaged by AFM. The image shows
that triangle-CpG assemble well and most of the particles
are shown as triangular shape. Based on the AFM image, the
diameter of triangle with 3 CpG is around 30 nm, a bit larger
than the original triangle.
FIG. 32 shows Dynamic Light Scattering (DLS) data
showing the mean diameter of triangle-3CpGs of 16.7 nM
and its agreement with AFM imaging data.
FIG. 33 shows how the RNA nanostructure triangle
protects CpG oligonucleotides from degradation in serum
over time.
FIG. 34 shows a Temperature Gradient Gel Electrophoresis (TGGE) ofRNAnanostructure triangle harboring CpG
oligonucleotides over increasing temperatures from 30° C.
to 80° C.
FIG. 35 shows a chart of relative cell viability vs. concentration from investigation of toxicity of RNA TriangleCpG.
FIG. 36 shows a flowcytometry study of 300 nM triangle
RNA harboring different numbers of CpGs binding to raw
264.7 cells. Positive binding: Triangle-lCpG 300 nM-Triangle-2CpGs 300 nM=Triangle-3Cpgs 300 nM>CpG 300
nM.
FIG. 37 shows a flowcytometry study of 1500 nM triangle
RNA harboring different numbers of CpGs binding to raw
264.7 cells. Positive binding: Triangle-lCpG 150
nM=Triangle 2CpGs 15-nM=Triangle-3CpGs 150 nM>CpG
150 nM.
FIG. 38 shows a flowcytometry study of 75 nM triangle
RNA harboring different numbers of CpGs binding to raw
264.7 cells. Positive binding: Triangle-lCpG 75
nM=Triangle-2CpGs 75 nM=Triangle-3CpGs 75 nM>CpG
75 nM.
FIG. 39 shows a flowcytometry study of37.5 nM triangle
RNA harboring different numbers of CpGs binding to raw
264.7 cells. Positive binding: Triangle-lCpG 37.5
nM=Triangle 2CpGs 37.5 nM=Triangle-3CpGs 37.5
nM>CpG 37.5 nM.
FIG. 40 shows a flowcytometry studying different concentration of triangle-lCpG binding to raw 264.7 cells.
Positive binding: Triangle-lCpG 300 nM>Triangle-lCpG
150 nM>Triangle-lCpG 75 nM>Triangle-lCpG 37.5 nM.
FIG. 41 shows a flowcytometry studying different concentration of triangle-2CpGs binding to raw 264.7 cells.
Positive binding: Triangle-2CpG 300 nM>Triangle-2CpG
150 nM>Triangle-2CpG 75 nM>Triangle-2CpG 37.5 nM.
FIG. 42 shows a flowcytometry studying different concentration of triangle-3CpGs binding to raw 264.7 cells.
Positive binding: Triangle-3CpG 300 nM>Triangle-3CpG
150 nM>Triangle-3CpG 75 nM>Triangle-3CpG 37.5 nM.
FIG. 43 shows a flowcytometry studying different concentration of CpG binding to raw 264.7 cells. Positive
binding: CpG 300 nM>CpG 150 nM>CpG 75 nM>CpG
37.5 nM.
FIG. 44 shows a table showing differing concentrations of
CpG, Triangle-lCpG, Triangle-2CpGs, and Triangle-3CpGs
and their respective levels of binding. Triangle-lCpG, Triangle-2CpGs and Triangle-3CpGs all have much stronger
binding than CpG only. Triangle should enhance the delivery
of CpG, which is also in agreement with the previous
cytokine data (stronger binding correlates to stronger
cytokine induction).
FIG. 45 shows a flowcytometry comparing square RNA
harboring different number of CpGs binding to raw 264.7
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cells. Positive binding: Square-I CpG=Square-2CpGs1=Square-2CpGs-2=Square-3CpGs=Square-4CpGs>CpG
Only
FIG. 46 shows a flowcytometry comparing pentagon
RNA harboring different number of CpGs binding to raw
264.7 cells. Positive binding: Pentagon-5CpG=Pentagon4CpG=Pentagon-3CpGs-l =Pentagon-3CpGs-2=Pentagon2CpGs- l =Pentagon-2CpGs-2>Pentagon-1 CpG>CpG only.
FIG. 47 shows a flowcytometry comparing triangle3CpG, square-4CpG, and pentagon-5CpG RNA nanostructures binding to raw 264.7 cells. Positive binding: Pentagon5CpG=Square-4CpG=Triangle-3CpG>CpG only.
FIG. 48 shows confocal imaging of triangle-CpG interacting with raw cells.
FIG. 49 shows confocal imaging of triangle-CpG interacting with raw cells.
FIG. 50 shows fluorescent imaging of morphology
changes oftriangle-CpG induced raw cells. Upon treatment
with triangle-CpG or CpG, the cell morphology changed
from a round form to an elongated form with more spreading
and forming pseudopodia.
FIG. 51 shows results of TNF-alpha cytokine ELISA
assay for 1) Triangle-CpG compared to Triangle RNA, CpG,
cell only, and blank medium and 2) increasing concentration
of Triangle-CpG.
FIG. 52 shows IL-6 cytokine ELISA assay for 1) TriangleCpG compared to Triangle RNA, CpG, cell only, and blank
medium and 2) increasing concentration of Triangle-CpG.
FIG. 53 shows a chart comparing TNF-alpha cytokine
ELISA assay for RNA triangles harboring different numbers
ofCpG.
FIG. 54 shows a chart comparing TNF-alpha cytokine
ELISA assay for RNA squares harboring different numbers
ofCpG.
FIG. 55 shows a chart comparing TNF-alpha cytokine
ELISA assay for RNA pentagons harboring different numbers ofCpG.
FIG. 56 shows a schematic showing self-assembly of
RNA triangle nanostructure harboring CpG RNAs, and the
CpG RNA sequences with 21 nucleotide overhang and 5U
linker.
FIG. 57 shows the sequence of A21 CpGRNA, the 63
nucleotide DNA, the 5' Primer and the 3' Primer.
FIG. 58 shows the sequence of B21 CpGRNA, the 63
nucleotide DNA, the 5' Primer and the 3' Primer.
FIG. 59 shows the sequence of C21 CpGRNA, the 63
nucleotide DNA, the 5' Primer and the 3' Primer.
FIG. 60 shows the PCR of the DNA templates for A21,
B21 and C21 CpG RNA.
FIG. 61 shows the image of 2'F CpG RNA made by in
vitro transcription.
FIG. 62 shows a summary of data of the cytokine testing
of 2'F RNA triangle harboring DNA CpG, DNA triangle
harboring DNA CpG, and 2'F RNA triangle harboring 2'F
RNACpG.
FIG. 63 shows the design of an RNA Nanostructure
Triangle with RNA CpG motif. Figure discloses SEQ ID
NOS 89-93, respectively, in order of appearance.

SEQ ID NO 3 is an exemplary RNA sequence for Triangle
short strand C used in assembly of an RNA triangle nanostructure.
SEQ ID NO 4 is an exemplary RNA sequence for Triangle
long strand D used in assembly of an RNA triangle nanostructure.
SEQ ID NO 5 is an exemplary RNA sequence for Square
short strand A used in assembly of an RNA square nanostructure.
SEQ ID NO 6 is an exemplary RNA sequence for Square
short strand B used in assembly of an RNA square nanostructure.
SEQ ID NO 7 is an exemplary RNA sequence for Square
short strand C used in assembly of an RNA square nanostructure.
SEQ ID NO 8 is an exemplary RNA sequence for Square
short strand D used in assembly of an RNA square nanostructure.
SEQ ID NO 9 is an exemplary RNA sequence for Square
long strand E used in assembly of an RNA square nanostructure.
SEQ ID NO 10 is an exemplary RNA sequence for
pentagon short strand A used in assembly of an RNA
pentagon nanostructure.
SEQ ID NO 11 is an exemplary RNA sequence for
pentagon short strand B used in assembly of an RNA
pentagon nanostructure.
SEQ ID NO 12 is an exemplary RNA sequence for
pentagon short strand C used in assembly of an RNA
pentagon nanostructure.
SEQ ID NO 13 is an exemplary RNA sequence for
pentagon short strand D used in assembly of an RNA
pentagon nanostructure.
SEQ ID NO 14 is an exemplary RNA sequence for
pentagon short strand E used in assembly of an RNA
pentagon nanostructure.
SEQ ID NO 15 is an exemplary RNA sequence for
pentagon long strand F used in assembly of an RNA
pentagon nanostructure.
SEQ ID NO 16 is an exemplary strand A21 CpG RNA.
SEQ ID NO 17 is an exemplary strand A21 CpG DNA.
SEQ ID NO 18 is an exemplary strand B21 CpG RNA.
SEQ ID NO 19 is an exemplary strand B21 CpG DNA.
SEQ ID NO 20 is an exemplary strand C21 CpG RNA.
SEQ ID NO 21 is an exemplary strand C21 CpG DNA.
SEQ ID NO 22 is an exemplary RNA sequence Tri A-Cpg
for assembly of RNA Triangle harboring RNA CpG motif.
SEQ ID NO 23 is an exemplary RNA sequence Tri B-CpG
for assembly of RNA Triangle harboring RNA CpG motif.
SEQ ID NO 24 is an exemplary RNA sequence Tri C-CpG
for assembly of RNA Triangle harboring RNA CpG motif.
SEQ ID NO: 25 is a 63 nucleotide DNA sequence
including the sequence of SEQ ID NO: 17, and SEQ ID NO:
26 and SEQ ID NO: 27 are 5'- and 3'-primers, as set forth in
FIG. 57.
SEQ ID NO: 28 is a 63 nucleotide DNA sequence
including the sequence of SEQ ID NO: 19, and SEQ ID NO:
29 and SEQ ID NO: 30 are 5'- and 3'-primers, as set forth in
FIG. 58.
SEQ ID NO: 31 is a 63 nucleotide DNA sequence
including the sequence of SEQ ID NO: 21, and SEQ ID NO:
32 and SEQ ID NO: 33 are 5'- and 3'-primers, as set forth in
FIG. 59.

DESCRIPTION OF THE SEQUENCE LISTING
SEQ ID NO 1 is an exemplary RNA sequence for Triangle
short strand A used in assembly of an RNA triangle nanostructure.
SEQ ID NO 2 is an exemplary RNA sequence for Triangle
short strand B used in assembly of an RNA triangle nanostructure.
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Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
In certain instances, nucleotides and polypeptides disclosed herein are included in publicly-available databases,
such as GENBANK® and SWISSPROT. Information
including sequences and other information related to such
nucleotides and polypeptides included in such publiclyavailable databases are expressly incorporated by reference.
Unless otherwise indicated or apparent the references to
such publicly-available databases are references to the most
recent version of the database as of the filing date of this
Application.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" comprises a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about" can encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method. For
example, the term "about" can refer to a value or an amount
of mass, weight, time, volume, concentration, percentage,
number, or temperature.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
As used herein, the term "sequence identity", "sequence
similarity" or "homology" is used to describe sequence
relationships between two or more nucleotide sequences.

The percentage of "sequence identity" between two
sequences is determined by comparing two optimally
aligned sequences over a comparison window, wherein the
portion of the sequence in the comparison window may
comprise additions or deletions (i.e., gaps) as compared to
the reference sequence (which does not comprise additions
or deletions) for optimal alignment of the two sequences.
The percentage is calculated by determining the number of
positions at which the identical nucleic acid base or amino
acid residue occurs in both sequences to yield the number of
matched positions, dividing the number of matched positions by the total number of positions in the window of
comparison, and multiplying the result by 100 to yield the
percentage of sequence identity. A sequence that is identical
at every position in comparison to a reference sequence is
said to be identical to the reference sequence and vice-versa.
As used herein, "Adjuvant" refers to a composition,
chemical or biological agent given in combination with a
composition, an antibody, polynucleotide or polypeptide to
enhance its immunogenicity.
The area of biomimetic nanotechnology involves the
construction of nano-scale, supramolecular architectures utilizing modular units of functional nucleic acids. The aim is
to design nanostructures that undergo self-assembly in controllable and recyclable fashion. Ribonucleic acid (RNA)
was discovered as an attractive material to build nanoparticles via nanotechnology (1 ), offering a variety of structural
modules and motifs that can be manipulated into 1D, 2D and
3D architectures (for review see (2)). In the past decade, a
variety of geometric RNA nanoparticles and nano-scaffolds
have been obtained via the approaches of hand-in-hand
(1,3-5), foot-to-foot (6-9), branch extension (10-14), loopreceptor contact (15-17), 'sticky' or 'dangling' ends (6, 18,
19) and synthetic RNA-protein complex interactions (20).
These motifs are available in data bases and can be used to
build artificial nanostructures by manipulating their interchangeable units (21). Recently, RNA rolling cycle transcription has been utilized to generate RNA sponges (22,23).
In RNA tectonics approach, structural motifs like double
helices, loops and junctions can be isolated from large and
complex RNA molecules appearing in structural data bases
and used to build artificial nanostructures by manipulating
their interchangeable units (24,25). As such, previously
reported designs of RNA nanoparticles, e.g. tecto-square
(26), square-shaped nano-scaffolds (27,28), RNA nano-rings
(1, 5, 7, 9) or pRNA dimers, tetramers and hexamers (1, 7,
9, 29, 30), as well as RNA nano-cubes (19), RNA polyhedron (14), RNA bundles (6,31) and filaments (15,16) utilize
fundamental principles of RNA structure and folding (3236). Overall stability of conventional constructs though,
mainly relies on the stability of canonical and non-canonical
base pair (bp) forming by loop-loop, receptor-loop, or
'sticky-ends' with a number of pairing nucleotides usually
not exceeding six. A new approach is needed to increase
overall stability of RNA nanoparticles, one that uses naturally-selected stable RNA building blocks for structure
building, and the example is the 3WJ motif from pRNA of
bacteriophage phi29 DNA packaging motorional nucleic
acids. The aim is to design nanostructures that undergo
self-assembly in controllable and recyclable fashion. A new
approach is needed to increase overall stability of RNA
nanoparticles, one that uses naturally-selected stable RNA
building blocks for structure building. An example is the
3WJ motif from pRNA of bacteriophage phi29 DNA packaging motor. In addition to discovering that the pRNA-3WJ
shows exceptional stability under physiological conditions
and in the presence of strong denaturing agent (10,11),
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recent studies also suggest that the thermodynamic stability
of the 3WJ is entropy driven (37). Stable RNA polygons
have the potential to serve as a new generation of delivery
systems for immunomodulators.
Embodiments as described herein comprise compositions
and adjuvants useful for prophylactic and therapeutic treatment. For example, embodiments comprise immunostimulatory RNA-containing compositions and RNA nanoparticle-containing compositions. The compositions described
herein are safe, effective, versatile, and easy to manufacture,
offering new solutions to address unmet needs associated
with current approaches to vaccine design and development.
RNA can be used as a construction material, immunostimulatory agent, or a combination thereof for the development of new nanovaccines and adjuvants for disease prevention and treatment.
Ultrastable RNA nanoparticles comprising RNA, CpG
DNA, peptide antigen or protein antigen can be pre-designed in silica and fabricated by thermodynamically-driven
self-assembly. The fabricated RNA nanoparticle-based
nanovaccine and adjuvants have pre-defined stoichiometry,
size and structure, and are also thermodynamically ultrastable and resistant to degradation in serum. The cellular
uptake of the RNA nanoparticle-based nanovaccine and
adjuvants is greatly enhanced compared to CpG DNA only
and antigen only. The immune response induced by the RNA
nanoparticle-based nanovaccine and adjuvants will also be
greatly enhanced compared to CpG DNA only and antigen
only. The RNA nanoparticle-based nanovaccines and adjuvants could also be conjugated to a variety of targeting
ligands for targeting to B cells, T cells, dendritic cells,
macrophages, cancer cells, or a combination thereof. The
targeting ligands comprises but are not limited to folate,
RNA aptamers, DNA aptamers, or a combination thereof. In
certain embodiments, multiple targeting ligands can be
conjugated to one nanoparticle to enhance the targeting
efficacy.
ssRNA, dsRNA and siRNA have been shown to have
immunostimulatory activities. Embodiments as described
herein comprise an immunostimulatory agent comprising
chemically modified RNA. The chemically modified RNA
comprises immunostimulatory motifs which comprises, but
are not limited to, the CpG motif. Embodiments as described
herein further comprise vaccine and adjuvant platforms that
use the immunostimulatory RNA as one of the platform
components. Moreover, the immunostimulatory RNA can
also be incorporated into ultrastable RNA nanoparticles
comprising RNA, CpG DNA, peptide antigen or protein
antigen to form nanovaccines. The fabricated RNA nanoparticle-based nanovaccine and adjuvants have pre-defined
stoichiometry, size and structure, and are also thermodynamically ultrastable and resistant to degradation in serum.
The immune response induced by the immunostimulatory
RNA platform will be greatly enhanced compared to CpG
DNA only and antigen only. The immunostimulatory RNA
platform could also be conjugated to a variety of targeting
ligands for targeting to B cells, T cells, dendritic cells,
macrophages, cancer cells, or a combination thereof. The
targeting ligands comprise but are not limited to folate,
siRNA, shRNA, RNA aptamers, DNA aptamers, or a combination thereof. In certain embodiments, multiple targeting
ligands can be conjugated to one platform to enhance the
targeting efficacy. The vaccine platform according to the
invention and the adjuvants platform according to the invention are employed to treat or prevent various diseases
comprising, but not limited to, cancer, immunology, respi-

ratory, central nervous system, inflanimatory, cardiovascular, infectious diseases, drug and substance abuse, or a
combination thereof.
RNA-based compositions disclosed herein, including
RNA-nanoparticle-containing and RNA-oligonucleotidecontaining compositions, have a number of advantageous
features. Such advantages comprises the following. The
RNA-based compositions have defined size, structure and
stoichiometry, such that unpredictable side effects arising
from heterogeneous particles can be avoided. Due to the
multivalent nature of RNA nanoparticles, multiple antigen
and adjuvants could be incorporated into one particle for
achieving synergistic or enhanced immune repose such as
cytokine induction and antibody production. The nanosize
of the particles will facilitate tissue penetration and target to
important immune tissues or organs such as lymph nodes for
achieving targeted and enhanced immune stimulation. Multiple targeting ligands could be incorporated into one particle for achieving better targeting to immune cells such as
B cells, T cells, dendritic cells and macrophages. Economic
and easy fabrication of RNA-based compositions could be
performed in a cell-free system which allows for industrial
scale production and avoids possible contamination. RNA
nanoparticles are highly soluble and not prone to aggregation. They do not require any addition steps, such as linkage
to PEG to keep them stable in solution. RNA nanoparticles
are also thermodynamically stable. For example, the triangular shaped RNAnanoparticles are resistant to boiling. The
three-way junction RNA nanoparticles are resistant to SM
urea denaturation. Thus RNA nanoparticles will remain
intact and not disassociate at ultra-low concentrations in
vivo. 2'F-modified RNA-based compositions, for example,
are resistant to degradation in serum and stable in the blood.
The cellular uptake of the RNA nanoparticle-based nanovaccine and adjuvants is greatly enhanced compared to CpG
DNA only and antigen only. The immunostimulatory activity of the chemical modified RNA-based compositions disclosed herein is stronger than other adjuvants such as CpG
DNA. Due to the larger size of RNA nanoparticle-based
nanovaccine and adjuvants compared to antigen and adjuvants only, the in vivo half-life of RNA nanoparticle-based
nanovaccine and adjuvants is significantly prolonged, offering better pharmacokinetics profiles and better patient compliance. The immunostimulatory RNA can also be incorporated into ultrastable RNAnanoparticles composed of RNA,
CpG DNA, peptide antigen or protein antigen to form
nanovaccine. The fabricated RNA nanoparticle-based nanovaccine and adjuvants have pre-defined stoichiometry, size
and structure, and are also thermodynamically ultrastable
and resistant to degradation in serum. The immune response
induced by the immunostimulatory RNA platform will be
greatly enhanced compared to CpG DNA only and antigen
only. RNA-based compositions as described herein are ultrastable and resistant to degradation in serum, and can be
conjugated to ligands to target, for example, B, T, dendritic,
macrophage, cancer cells, or a combination thereof.
The presently-disclosed subject matter comprises a composition comprising an RNA-oligonucleotide and an immunostimulatory motif.
In some embodiments, the RNA-oligonucleotide comprises a chemical modification, examples of which comprise
2'Fluoro, 2'Amine, and 2'O-Methyl. In some embodiments,
the RNA-oligonucleotide comprises about 5, about 6, about
7, about 8, about 9, about 10, about 11, about 12, about 13,
about 14, about 15, about 16, about 17, about 18, about 19,
about 20, about 21, about 22, about 23, about 24, about 25,
about 26, about 27, about 28, about 29, about 30, about 31,
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about 32, about 33, about 34, about 35, about 36, about 37,
about 38, about 39, about 40, about 41, about 42, about 43,
about 44, about 45, about 46, about 47, about 48, about 49,
or about 50 bases in length. In some embodiments, the
RNA-oligonucleotide comprises at least one single-stranded
RNA oligonucleotide. In other embodiments, the RNAoligonucleotide comprises at least one double-stranded or
partially double-stranded (e.g., containing a hair-pin) RNA
oligonucleotide.
In some embodiments, the immunostimulatory motif
comprises an immunostimulatory RNA (isRNA) and a CpG
oligodeoxyribonucleotide (CpG). The isRNA can be any
isRNA known to the skilled artisan, examples of which are
set forth in Patent Application Publication Nos. US 2014/
0135487 and WO 2003/086280, which are incorporated by
reference in their entireties. In some embodiments, the
immunostimulatory motif is conjugated to the RNA-oligonucleotide. In some embodiments, the immunostimulatory
motif is CpG conjugated to the RNA-oligonucleotide.
In some embodiments, the composition comprising an
RNA-oligonucleotide and an immunostimulatory motif is
provided as an adjuvant. In some embodiments, the immune
modulation effect for cytokine induction is increased at least
about ten fold as compared to the immunostimulatory motif
provided independently of the RNA-oligonucleotide. In
some embodiments, the immune modulation effect for
cytokine induction is increased at least about two fold, three
fold, four fold, five fold, six fold, seven fold, eight fold, nine
fold, fifteen fold, twenty fold, thirty fold, forty fold, fifty fold
as compared to the immunostimulatory motif provided independently of the RNA-oligonucleotide. In some embodiments when immunostimulatory motif is conjugated to the
RNA-oligonucleotide, the immune modulation effect for
cytokine induction and cell binding is enhanced at least 10,
at least 20, at least 30, at least 40, at least 50, at least 7 5, at
least 100, at least 150, or at least 200 times.
Embodiments as described herein comprise a composition
comprising an RNA nanostructure, and an adjuvant, an
antigen, and/or a targeting ligand. Examples of RNA nanostructures comprise RNA triangle, RNA square, RNA pentagon, RNA hexagon, RNA three-way junction, RNA fourway junction
In some embodiments, the RNA nanostructure comprise
an RNA triangle, RNA square, RNA pentagon, RNA hexagon, RNA three-way junction, RNA four-way junction. In
some embodiments, the RNA nano structure is derived from
a 3WJ motif. A non-limiting example of the RNA nanostructure comprises an RNA nanostructure that is derived
from the 3WJ motif, such as that described in the Examples
herein. Other RNA nanostructures are known to those
skilled in the art, for example that which is found in
International Patent Application Publication No. WO 2012/
170372, which is incorporated by reference in its entirety.
In embodiments as described herein, the adjuvant comprises an immunostimulatory RNA (isRNA), a CpG oligodeoxyribonucleotide (CpG), or a combination thereof. In some
embodiments, the isRNA, can be about 5, about 6, about 7,
about 8, about 9, about 10, about 11, about 12, about 13,
about 14, about 15, about 16, about 17, about 18, about 19,
about 20, about 21, about 22, about 23, about 24, about 25,
about 26, about 27, about 28, about 29, about 30, about 31,
about 32, about 33, about 34, or about 35 bases in length. In
some embodiments the isRNA is about 8 to about 30 bases
in length. In some embodiments, the adjuvant comprises
isRNA and the isRNA is incorporated into the RNA nanoparticle by base pairing. In some embodiments, the adjuvant
comprises isRNA and the isRNA is incorporated into the

RNA nanoparticle by being covalently bonded to an RNA
strand of the RNA nanoparticle. In some embodiments, the
adjuvant comprises a composition as described herein, an
example of which comprises an RNA-oligonucleotide and
an immunostimulatory motif. In some embodiments, the
RNA-oligonucleotide and immunostimulatory motif are
incorporated into the RNA nanoparticle by base pairing
between the RNA-oligonucleotide and the RNA nanoparticle. In some embodiments, the RNA-oligonucleotide and
immunostimulatory motif are incorporated into the RNA
nanoparticle by the RNA-oligonucleotide being covalently
bonded to an RNA strand of the RNA nanoparticle.
Embodiments as described here comprise an antigen,
non-limiting examples of which can be derived from a
bacteria, virus, or cell. In some embodiments, the antigen
binds to a neutralizing antibody or an inhibitory antibody. In
some embodiments, the antigen comprises a neutralizing
epitope. In some embodiments, the antigen comprises a
B-cell epitope, T-cell epitope, T-helper epitope, epitopes
derived from PG120, gp41 epitopes, glycans, peptides,
T-helper peptides, streptavidin, or combination thereof.
Embodiments as described herein comprise a targeting
ligand, non-limiting examples of which comprise an
aptamer, a cell surface marker, a cancer cell, or a combination thereof. In some embodiments, where the targeting
ligand comprises an aptamer, the aptamer can bind to at least
one HIV epitope. In some embodiments, where the targeting
ligand comprises a cell surface marker, the cell surface
marker comprises a macrophage or a lymphocyte. In some
embodiments, the composition comprises at least two targeting ligands. In some embodiments, the composition comprises one, two, three, four, five, six, seven, eight, nine, or
ten targeting ligands. In some embodiments the multiple
targeting ligands are the same. In other embodiments, the
targeting ligands are different. In some embodiments, not all
of the multiple targeting ligands are the same.
As will be appreciated by the skilled artisan, compositions
disclosed herein can be formulated to comprises a pharmaceutically-acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" refers to sterile aqueous or
nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile
injectable solutions or dispersions just prior to use.
Examples of suitable aqueous and nonaqueous carriers,
diluents, solvents or vehicles comprises water, ethanol,
polyols (such as glycerol, propylene glycol, polyethylene
glycol and the like), carboxymethylcellulose and suitable
mixtures thereof, vegetable oils (such as olive oil) and
injectable organic esters such as ethyl oleate. Proper fluidity
can be maintained, for example, by the use of coating
materials such as lecithin, by the maintenance of the
required particle size in the case of dispersions and by the
use of surfactants. These compositions can also contain
adjuvants such as preservatives, wetting agents, emulsifying
agents and dispersing agents. Prevention of the action of
microorganisms can be ensured by the inclusion of various
antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be
desirable to include isotonic agents such as sugars, sodium
chloride and the like. Prolonged absorption of the injectable
pharmaceutical form can be brought about by the inclusion
of agents, such as aluminum monostearate and gelatin,
which delay absorption. Injectable depot forms are made by
forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio
of drug to polymer and the nature of the particular polymer
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employed, the rate of drug release can be controlled. Depot
injectable formulations are also prepared by entrapping the
drug in liposomes or microemulsions which are compatible
with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining
filter or by incorporating sterilizing agents in the form of
sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just
prior to use. Suitable inert carriers can comprise sugars such
as lactose. Desirably, at least 95% by weight of the particles
of the active ingredient have an effective particle size in the
range of 0.01 to 10 micrometers.
The presently-disclosed subject matter further comprises
methods as disclosed herein. For example, a method of
inducing an immune response in a subject comprises administering to the subject an effective amount of a composition
as described herein. In some embodiments, the subject has
or is at risk of having a pathological condition. Embodiments as described herein further comprises a method of
inducing the production of cytokines comprising administering to a subject an effective amount of a composition as
described herein. In some embodiments, the cytokines comprise TNF-alpha, IL-6, IL-12, or a combination thereof. The
presently-disclosed subject matter further comprises a
method of inducing the production of high affinity neutralizing antibodies or inhibitory antibodies comprising administering a composition as described herein to a subject
having a pathological condition. Exemplary pathological
conditions comprises, but are not limited to, cancer, immunology, respiratory, central nervous system, inflanmiatory,
cardiovascular, infectious diseases, influenza, human immunodeficiency virus (HIV), and drug and substance abuse,
such as cocaine or nicotine abuse.
As used herein, the term "subject" refers to a target of
administration. The subject of the herein described methods
can be a vertebrate, such as a manmial, a fish, a bird, a
reptile, or an amphibian. Thus, the subject of the herein
described methods can be a human or non-human. Thus,
veterinary therapeutic uses are provided in accordance with
the presently described subject matter. As such, the presently
described subject matter provides for administration to
mammals such as humans and non-human primates, as well
as those mammals of importance due to being endangered,
such as Siberian tigers; of economic importance, such as
animals raised on farms for consumption by humans; and/or
animals of social importance to humans, such as animals
kept as pets or in zoos. Examples of such animals comprise
but are not limited to carnivores such as cats and dogs;
swine, including pigs, hogs, and wild boars; ruminants
and/or ungulates such as cattle, oxen, sheep, giraffes, deer,
goats, bison, and camels; rabbits, guinea pigs, and rodents.
Also provided is the treatment of birds, including the treatment of those kinds of birds that are endangered and/or kept
in zoos, as well as fowl, and more particularly domesticated
fowl, i.e., poultry, such as turkeys, chickens, ducks, geese,
guinea fowl, and the like, as they are also of economic
importance to humans. Thus, also provided is the treatment
of livestock, including, but not limited to, domesticated
swine, ruminants, ungulates, horses (including race horses),
poultry, and the like. The term does not denote a particular
age or sex.
The presently-described subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may comprise compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.

EXAMPLES
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Modulation of immune response is important in cancer
immunotherapy, vaccine adjuvant development and inflammatory or immune disease therapy. Here we report the
development of new immunomodulators via control of
shape transition among RNA triangle, square and pentagon
nanostructures. Changing one RNA strand in polygons automatically induced the stretching of the interior angle from
60° to 90° or 108°, resulting in self-assembly of elegant
RNA triangles, squares and pentagons. When immunological adjuvants were incorporated, their immunomodulation
effect for cytokine TNF-a and IL-6 induction was greatly
enhanced in vitro and in animals up to 100-fold, while RNA
polygon controls induced unnoticeable effect. The RNA
nanoparticles were delivered to macrophages specifically.
The degree of immunostimulation greatly depended on the
size, shape and number of the payload per nanoparticles.
Stronger immune response was observed when the number
of adjuvants per polygon was increased, demonstrating the
advantage of shape transition from triangle to pentagon.
By stretching the 60° AOB angle (L) (FIG. 1) of the
thermodynamically stable pRNA 3WJ motif, stable RNA
architectures can be designed. We demonstrate that it can be
stretched to wide conformations resulting in different 2D
polygons: triangle (LAOB=) 60°, square (LAOB=90°) and
pentagon (LAOB=108°). Intermolecular interactions such
as kissing loops, receptor loop, or 'sticky-ends' were
avoided by introducing linkages through base pairing
between corners of the polygons using RNA double helices.
Therefore, this system is advantageous with an increased
thermo-stability in the overall construct.
We further demonstrate that the RNA polygons have the
potential to serve as a new generation of delivery systems for
immunomodulators. Synthetic unmethylated cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are
immunostimulatory DNA molecules that mimic the immunostimulatory activity of bacterial DNA (38,39). CpG DNA
motifs strongly activate the mammalian innate immune
system by interacting with various immune cells via endosomal Toll-like receptor 9 (TLR9) (40,41). Upon the stimulation by CpG DNA, immune cells could secret a variety of
proinflanmiatory and antiviral cytokines including tumor
necrosis factor-alpha (TNF-alpha, or TNF-a), interleukin-6
(IL-6), interleukin-12 (IL-12) and interferon (IFN), which
leads to potent immune response. The therapeutic potential
of CpG DNA has also been extensively explored in both
basic research and human clinical trials, including the development of new vaccine adjuvants, anticancer agents, immunoprotective agents and anti-allergic agents (42-45).
Recently, several groups have reported the utilization of
DNA nano structures such as DNA tetrahedrons (46), DNA
polypod-like structures (47), DNA origami structures (48),
Y-shaped DNA (49) and DNA dendrimers (50) to deliver
immunostimulatory CpG DNA. In this work, to the best of
our knowledge, we report the first use of RNA nanostructures to deliver CpG DNA in vitro and in vivo. The immunostimulatory efficacy of RNA polygons was evaluated by
measuring the release of cytokines. We found that the
induction of cytokines is highly dependent on the number of
CpG per polygon. With increasing number of CpG per
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polygon, stronger immune response was observed, demonstrating the advantage of the transition from a triangle to a
pentagon that can carry five CpGs.
We also report RNA CpG. The characteristic of RNA that
differentiates it from DNA is the 2'-hydroxyl (2'-OH) on
each ribose sugar of the backbone. The 2'-OH group offers
RNA a special property. From a structural point of view, the
advantage of this additional hydroxyl group is that it locks
the ribose sugar into a 3'-endo chair conformation, and it will
be structurally favorable for the RNA double helix to adopt
the A-form helix rather than the B-form helix that is typically present in the DNA. From a thermodynamic point of
view, remarkably, the RNA double helix is more thermodynamically stable than the DNA double helix considering
llG0 for RNA double helix formation is -3.6 to -8.5
kJmol-1 per base pair stacked and llG0 for DNA double
helix formation is -1.4 kJmol-1 per base pair stacked.
Moreover, the presence of special structures such as bends,
stacks, junctions and loops in the 3D structure of RNA as
well as various proteins and metal ions may also further
improve its stability. Similar to DNA CpG sequence, RNA
CpG sequence can also induce immune response and can be
applied to the development of cancer immunotherapy and
vaccine adjuvants.

Materials and Methods
RNANanoparticles Design, Synthesis and Self-Assembly
The 3WJ crystal structure of the pRNA molecule (PDB
ID: 4KZ2) was primarily used for designing polygon models
using Swiss PDB viewer, as previously described (51). RNA
strands for corresponding triangle, square and pentagon,
were synthesized by in vitro T7 transcription using polymerase chain reaction (PCR) generated DNA templates.
RNAs were purified by denaturing polyacrylamide gel electrophoresis (PAGE) and were either Cy5 whole body RNA
labeled (Minis Bio LLC) or 5'-end [-32P] ATP (PerkinElmer) labeled, as previously described (8).
RNA polygons were assembled in one pot by mixing
equimolar concentrations (final concentration of 1 IIM) of
four RNA strands for the triangle, five RNA strands for the
square and six RNA strands for the pentagon in 1xTMS
buffer (50 mM TRIS pH 8.0, 100 mM NaCl and 10 mM
MgC12). Samples were annealed for 1 h in a thermocycler
with controlled, slow cooling (1 ° C./min) from 80 to 4° C.
All RNA polygons harboring CpG ODNs were assembled
from their corresponding 2'F-U/C modified strands in one
pot.
The three short RNA strands and one long RNA strands
for assembly of the RNA polygon are provided in Table 1.
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TABLE 1
RNA Triangle Nanostructure

SEQ.
ID NO

RNA Sequence
Triangle short 5'GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUACUUUG
strand A
UUGCACGCAC -3'

1

Triangle Short 5'GGGAGCGUGCAAUCAUGGCAACGAUAGAGCAUACUUUG
Strand B
UUGGCUGGAC -3'

2

Triangle Short 5'GGGACCAGCCAAUCAUGGCAAUAUACACGCAUACUUUG
Strand C
UUGACGGCGG -3'

3

Triangle Long
Strand D

4

5'GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUG
UAUGCUCUAUCGUUGUCAUGUGUAUGGC -3'

The four short strands and one long strand for assembly
of the square RNA nanostructure are provided in Table 2.

TABLE 2
RNA Square Nanostructure
RNA Sequence

SEQ. ID NO

Square Short 5'GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUAC
Strand A
UUUGUUGCACGCAC -3'

5

Square Short 5'GGGAGCGUGCAAUCAUGGCAAGCGCAUCGCAUAC
Strand B
UUUGUUGCGACCUA -3'

6

Square Short 5'GGGAGGUCGCAAUCAUGGCAACGAUAGAGCAUA
Strand C
CUUUGUUGGCUGGAC -3'

7

Square Short 5'GGGACCAGCCAAUCAUGGCAAUAUACACGCAUAC
Strand D
UUUGUUGACGGCGG -3'

8

Square Long
Strand E

9

5'GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUC
AUGUGUAUGCUCUAUCGUUGUCAUGUGUAUGCGA
UGCGCUUGUCAUGUGUAUGGC -3'
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The five short strands and one long strand for assembly of
the pentagon RNA nanostructure are provided in Table 3.

TABLE 3
RNA Pentagon Nanostructure
SEQ. ID NO

RNA Sequence
Pentagon Short 5'GGGAGCCGUCAAUCAUGGCAAGUGUCCGCCAUAC
Strand A
UUUGUUGUAGGGCA -3'

10

Pentagon Short 5'GGGACCCUACAAUCAUGGCAAAUAUGCGCCAUAC
Strand B
UUUGUUGCACGCAC -3'

11

Pentagon Short 5'GGGAGCGUGCAAUCAUGGCAAGCGCAUCGCAUAC
Strand C
UUUGUUGCGACCUA -3'

12

Pentagon Short 5'GGGAGGUCGCAAUCAUGGCAACGAUAGAGCAUA
Strand D
CUUUGUUGGCUGGAG -3'

13

Pentagon Short 5'GGGACCAGCCAAUCAUGGCAAUAUACACGCAUAC
Strand E
UUUGUUGACGGCGG -3'

14

Pentagon Long
Strand F

15

5'GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUC
AUGUGUAUGCUCUAUCGUUGUCAUGUGUAUGCGA
UGCGCUUGUCAUGUGUAUGGCGCAUAUUUGUCAUG
UGUAUGGC -3'

25

Table 4 provides sequences for CpG motifs.

TABLE 3
CG motifs

RNA Sequence

A21 CpG

B21 CpG

30

SEQ.
ID NO

5'-UCCAUGACG UUCCUGACGU UUUUUUUACA
GUCGUAUUGC AUUCCGA-3'

16

5'-TCCATGACG TTCCTGACGT TTTTTTTACA
GTCGTATTGC ATTCCGA-3'

17

5'-UCCAUGACGU UCCUGACGUU UUUUUCCAUA
CCGCCAUUUC CAACUA-3'

18

5'-TCCATGACGT TCCTGACGTT TTTTTCCATA
CCGCCATTTC CAACTA-3'

19

5'-UCCAUGACGU UCCUGACGUU UUUUUAAGCA
CAUGCGAUGU UUAACU-3'

20

5'-TCCATGACGT TCCTGACGTT TTTTTAAGCA
CATGCGATGT TTAACT-3'

21
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C21 CpG
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Table 5 provides the sequences for the RNA Triangle
harboring the RNA CpG motif.
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TABLE 5
RNA Triangle Nanostructure Harboring RNA CpG motif
RNA Sequence and
DNA Sequence

SEQ.

55

ID NO

Tri A-CpG 5'- GGUCCAUGAC GUUCCUGACG UUUUUUUGGG
CCGUCAAU CAUGGCAAGU GUCCGC CAUAC UUU
GUUGCACGCC C -3'

22

Tri B-CpG 5'- GGUCCAUGAC GUUCCUGACG UUUUUUUGGG
CGUGCAAU CAUGGCAACG AUAGAGCAUA C UUU
GUUGGCUGGC C -3'

23

Tri C-CpG 5'- GGUCCAUGAC GUUCCUGACG UUUUUUUGGC
CAGCCAAU CAUGGCAAUA UACACGCAUA C UUU
GUUGACGGCC C -3'
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Native PAGE, Temperature Gradient Gel Electrophoresis
(TGGE) and Boiling Resistance Assays
RNA assemblies were evaluated on 7% (29:1) native
poly-acrylamide gels in the presence of 0.5xTMS buffer.
Gels were run at constant 90 V, +4 ° C. Gels were imaged
with Typhoon FLA 7000 (GE Healthcare) to visualize RNA
strands. Temperature gradient gel electrophoresis (TGGE)
analysis was performed on 7% native PAGE in a buffer
containing 50 mM TRIS pH 8.0, 100 mM NaCl and 0.2 mM
MgC12, as previously described (14, 26, 28). A gradient
temperature of 30-70° C. was applied perpendicular to
electrical current and the experiment was run for 1 h at 20
W. A total RNA concentration of 100 nM was used in TGGE
analysis. Apparent TM values corresponded to the temperature at which half of the polygons fractions were dissociated
and apparent KD values for multiple RNA strands were
calculated, as described previously (7).
Boiling resistance assay was performed in 10 III containing 1 IIM preassembled polygons in TMS buffer or in the
presence of SM urea. Samples were incubated at 100° C. for
several minutes, then snap cooled on dry ice to prevent
refolding following evaluation on 7% native PAGE at 4° C.
Individual experiments were repeated several times to
reduce error.
Quantification analysis was performed using ImageJ (52).
Equal-sized boxes were drawn around the lanes corresponding to the triangle, square, or pentagon complexes and
corresponding quantified values for each type of polygon
were divided by the sum of the values presented in the
corresponding lane.
Cell Cultures
Mouse macrophage-like RAW 264.7 cells were grown in
Dulbecco's Modified Eagle's Medium supplemented with
10% fetal bovine serum, 100 units/ml penicillin and 100
mg/ml streptomycin at 37° C. in humidified air containing
5% CO2. Cells were then seeded on 24-well plates or
96-well plates at a density of 5x105 cells/ml and cultured
overnight before use.
Cytokine Secretion from RAW264.7 Cells
RAW 264.7 cells were plated into 24-well plates with the
density of 2.5x105 cells per well and cultured overnight.
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Then, RNA nanoparticles harboring different numbers of
CpG ODNs were diluted in Opti-MEM medium (Life Technologies Corporation, Carlsbad, Calif., USA) and added to
the cells. The cells were continually cultured for 8 hat 37°
C. in humidified air containing 5% CO2, and the cell culture
supernatant were collected and stored at -80° C. until use.
The concentration of TNF-a and IL-6 in the supernatant
were determined by enzyme-linked immunosorbent assay
(ELISA) using Mouse ELISA MAX™ Deluxe sets (BioLegend, Inc., San Diego, Calif.), following protocols provided
by the manufacturer.
Cytokine Secretion from Mice
Male CD-1 mice (4-5 weeks old) were purchased from
Charles River Laboratories. All animal procedures were
approved by the Institutional Animal Care and Use Committee at University of Kentucky and were performed in
accordance with guidelines issued by the National Institutes
of Health for the care of laboratory animals. For in vivo
immunostimulation, RNA triangular nanoparticles harboring CpG ODN, RNA triangular nanoparticles, or CpG ODN
were dissolved in phosphate buffered saline (PBS) and
administrated to the mice via tail vein injection at 2 mg/kg
(CpG ODN per body weight). The same volume of PBS was
injected into a mouse as a control. Blood samples were
collected 3 h post-injection by cardiac puncture. Serum was
prepared by centrifugation at 12 800 g for 10 min. Serum
TNF-a and IL-6 levels were determined by enzyme-linked
immunosorbent assay (ELISA) using Mouse ELISA
MAX™ Deluxe sets (BioLegend, Inc., San Diego, Calif.,
USA), following protocols provided by the manufacturer.
Confocal Microscopy Imaging
RAW 264.7 cells were seeded on glass coverslips in
24-well plates and cultured at 37° C. in humidified air
containing 5% CO2 overnight. The culture medium was
removed and the cells were washed with Opti-MEM
medium twice to remove dead cells. RNA nanoparticles
harboring Cy3-labeled CpG DNA or Cy3-labeled CpG DNA
only were diluted in Opti-MEM medium and added to the
cells. After 4 h incubation at 37° C. in humidified air
containing 5% CO2, the cells were washed twice with PBS
and fixed with 4% formaldehyde. ProLong R GoldAntifade
Reagent with DAPI (Life Technologies Corporation, Carlsbad, Calif.) was used to stain the cell nucleus and mount the
samples. Alexa FluorR 488 phalloidin (Life Technologies
Corporation, Carlsbad, Calif., USA) was used to stain actin.
The images were obtained on a Olympus FVl 000 confocal
microscope (Olympus Corporation, Tokyo, Japan).
Atomic Force Microscopy Imaging
RNA polygons were imaged with MultiModeAFM NanoScope IV system (Veeco ), as per previously reported methods (61). Briefly, the RNA samples were diluted with
lxTMS buffer to a final concentration of 3-5 nM. Then,
droplets of samples ( 5-10 L) were immediately deposited on
APS mica. After 2 min incubation on the specifically modifiedAPS mica surface (41;42), excess samples were washed
with DEPC treated water and dried under a flow of Argon
gas. AFM images in air were acquired using MultiMode
AFM NanoScope IV system (Veeco/Digital Instruments,
Santa Barbara, Calif.) operating in tapping mode.
Dynamic Light Scattering
Apparent hydrodynamic sizes of preassembled triangle,
square, and pentagon complexes (10 µM) in 504, TMS
buffer were measured by Zetasizer nano-ZS (Malvern
Instrument, LTD) at 25° C. The laser wavelength was 633
nm.

Flow Cytometry Assay
RAW264.7 cells were detached from the cell culture flask
by using a cell scraper. The cells were washed with OptiMEM medium and aliquot in 1.5 mL Eppendorf tubes at the
density of 5xl 05 cells per tube. RNA nanoparticles harboring Cy3-labeled CpG DNA or Cy3-labeled CpG DNA only
were diluted in Opti-MEM medium and incubated with the
cells at 37° C. for 1.5 h. The cells were vortexed every 30
min during the incubation. After washing with PBS, the cells
were resuspended in PBS and the intensity of fluorescence
was determined by FACSCalibur flow cytometer (BD Biosciences, San Jose, Calif.).
Cytotoxicity Assay
The cytotoxicity of RNA nanoparticles harboring CpG
ODNs was evaluated with an MTT assay kit (Promega,
Madison, Wis.), according to the protocol provided by the
manufacturer. Briefly, RAW 264.7 cells were seeded at 96
well plates and cultured overnight at 3 7° C. in humidified air
containing 5% CO2. RNA nanoparticles harboring CpG
ODNs and controls were dissolved in fresh cell culture
medium at the indicated concentrations and added to the
cells for incubation at 3 7° C. for 24 h. Then, 15 µL of the dye
solution was added to each well, followed by a 4 h incubation at 37° C., Next, 100 µl of the solubilization solution was
added to each well and the plate was future incubated at
room temperature on a plate shaker until the formazan
crystals were completely solubilized. The absorbance was
measured at 570 nm using a microplate reader. The cell
viability was calculated relative to the absorbance of the cell
only control (viability of cell only control=!).
RNA Polygons: Triangle, Square and Pentagon Fabrication and Self-Assembly
The structural features of the recently discovered ultrastable pRNA 3WJ module from the bacteriophage Phi29 DNA
packaging motor were utilized for in silica design of the
RNA triangle, square and pentagon 2D polygons. During the
computer modeling we used the particular angle of the 3WJ
formed by Hl and H2 as an inner angle of the polygons as
we hypothesized that the angle could be stretched to a more
open conformation. Throughout this report the intra-helical
angle between Hl and H2 is denoted as LAOB, as shown in
FIG. 1. Each RNA model contained a pRNA 3WJ motif at
each vertex, and the inner angles correspond to LAOB. The
resulting 3D models exhibited flat conformations, as
expected from the plane geometry of the 3WJ motif (51)
(FIG. 2A). As used herein, vertex refers to a point of an
angle, such as LAOB, and vertex refers to a corner of a
polygon. By way of example, and with reference FIG. 2B,
the triangular polygon defined by internal strand D and
external strands A, B, and C, includes three vertexes; the
square polygon defined by internal strand E and external
strands A, B, C, and D, includes four vertexes; and the
pentagon polygon defined by internal strand F and external
strands A, B, C, D, and E, includes five vertexes.
Each polygon was composed of a different number of
RNA strands classified as short strands (external) and long
strands (internal) (FIG. 2B). By increasing the number of
external strands and the propagation of the central or internal
strand, the tension on the inter-helical LAOB increased to
60°, 90° and 108°, allowing for 2D formation of corresponding triangle, square and pentagon shapes. The measured
widths, from one corner to another, were 10.2 nm, while the
heights differed as follows: triangle=9.1 nm, square=l0.2
nm and pentagon=12.7 nm. Following the transcription of
individual RNA strands, self-assembly properties of the
triangle, square and pentagon designs were evaluated on 7%
native polyacrylamide gel electrophoresis (PAGE) (FIG.
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2C). All polygon formations were obtained by one-step
self-assembly (7, 10, 11, 19). Each RNA component of
corresponding nanoparticles were whole chain labeled with
Cy5 to evaluate participation of all RNA strands in their
corresponding assemblies. Yield of correctly assembled
polygons was estimated to be >90% based on native PAGE
gel evaluations. Equilibrium constants of dissociation were
obtained from apparent KD gels, and KD values were
determined to be 18.8, 20.3 and 22.5 nM for triangles,
squares and pentagons, respectively (FIGS. 7 and 8).
These results demonstrate that each RNA nanoparticle
assembles into the desired nanostructure, and indicated by a
stretching of the 60. LAOB to wider conformations. The
assembly of RNA strands into specific-shaped nanoparticles
based on the 60. LAOB of the pRNA 3WJ motif was
controlled by modulating the number of short external
stands and the length of the long internal strand.
Structural Characterization of Polygons by Atomic Force
Microscopy (AFM) and DLS
To further evaluate the size and shape of the resulting
RNA assemblies, structural characterization of each polygon
was conducted by AFM. AFM images of the pRNA 3WJ
based polygons revealed that the shapes of resulting polygons were similar to their predicted, theoretical 3D models
(FIG. 3A). The estimated average dimensions were found to
be 13±1.1, 14±1.8 and 17±1.6 nm for triangles, squares and
pentagons, respectively. These values do not reflect the true
sizes of the RNA polygons due to the AFM tip convolution,
but rather demonstrate that the average size of the nanoparticles increases from triangle to pentagon. In addition, the
central cavity of each RNA shape is visible, and the size of
the cavity gradually increases with the number of polygon
vertices. The measured heights for all nanoparticles was
found to be 2 nm, in agreement with previously reported
heights of nucleic acid double helices (26,53).
Quantification analysis was performed to compare apparent yields between polygons observed on AFM mica surface.
Equal concentrations (1 nM) of the polygons were deposited on a mica surface and correctly folded polygons were
manually counted in a 0.5 µm 2 area, resulting in 48 triangular particles, 33 square particles and 17 pentagon nanoparticles (FIG. 9). The estimated number of triangular nanoparticles adsorbed on the mica was 1.5 times more than that
of the square and three times more than that of the pentagon.
However, native PAGE revealed that the yields among the
three polygons were almost equal. The difference in adsorption amounts between polygons on the mica surface was
presumably due to variation in their sizes and 3D conformations, resulting in different dynamic and physical properties.
Hydrodynamic Diameters of the Polygons by DLS was
performed to determine the apparent hydrodynamic diameters for each of the polygons.
DLS was performed to determine the apparent hydrodynamic diameters for each of the polygons. The diameters
were found to be 9 .1, 11.2 and 13 .5 nm for triangles, squares
and pentagons, respectively (FIG. 3B). The increase in
number of 3WJ cores corresponds with the larger observed
diameter. The measured diameters agreed with their corresponding 3D models. However, there was a discrepancy
between polygon sizes determined by AFM and DLS. This
could be attributed to the fundamentally different techniques, as DLS determines the average size distribution
profile of nanoparticles in solution assuming that the polygons have globular shapes [refer to manual at http://www.
malvern.com], while AFM imaging can produce images

larger than the real diameter due to tip size used (54) and the
resolution of imaging equipment. Nevertheless, the two
techniques demonstrated that the relative size of the nanoparticles increased from triangle to square to pentagon.
Accordingly, native PAGE, AFM and DLS showed the
formation of compact molecular 2D assemblies of triangle,
square and pentagon based on the pRNA 3WJ LAOB.
Consequently, the naturally preserved 60° LAOB could
be stretched to reach the formation of square and pentagon.
The stretching, or tension, that the angle underwent could
have had a significant impact on the overall stability of the
nanoparticles. Therefore, it was of great interest to evaluate
and compare the polygon's stabilities.
Stability Comparison Between Triangle, Square and Pentagon
TGGE Investigation of Polygon Stability
The stabilities of polygons were studied using a perpendicular TGGE (Biometra GmbH). This convenient technique has garnered widespread use for measuring melting
temperatures of RNA nanoparticles with multiple strands (5,
7, 14, 26, 28, 55). The preassembled polygons were subjected to 7% native TGGE with a gradient temperature of
30-70° C. perpendicular to electrical current. The following
apparent TM values were obtained for the polygons at 100
nM total concentration (Ct) in presence of 0.2 mM MgC12:
triangle TM=56° C., square TM=53° C. and pentagon
TM=50° C. (FIG. 4A). The triangular nanoscaffolds were
more stable than squares and pentagons, although the number of RNA bp was much higher in the pentagon construct,
as compared to the square and triangle. Usually, the stability
of nucleic acids with the same base-pair content is directly
dependent on metal ion and total nucleic acid concentrations. Since these two criteria were the same, it was assumed
that the higher the number of bp in a given RNA structure
the higher the stability. Therefore, the most stable shape
produced should be the pentagon. However, based on TGGE
data the opposite was found. This was likely due to the
tension caused by the stretching of the native pRNA 3WJ
60° LAOB. The triangular construct angle was preserved
(60°), the square and pentagon angles were stretched to the
wider conformations of 90° and 108°, respectively. Previously it has been shown that any nucleotide mutations or
deletions within the native core structure of the pRNA 3WJ
motif would also result in the loss of its thermodynamic
stability (10). Interestingly, the measured triangle and square
TM values differed by +3° C., as did the square and
pentagon. Boiling resistance assay in the presence and
absence of 8 M urea further confirmed that the triangle was
the most stable nanoparticle (FIG. 4B). The quantification of
nanoparticle bands after heating to 100° C. resulted in
75±4% recovery of the triangular assembly, suggesting a
TM> 100° C. By definition, TM is the measured temperature
when half the RNA concentration has melted, i.e. 50%
recovery. The percentage of recovery for square was 28±2%
and for pentagon was 16±5%, much lower than the value
estimated for triangle recovery. The experiment with the
presence of 8 M urea in boiling solution showed that the
overall trend of stability remained the same, but the percentage of recovery was 55±4% for triangle, 8±3% for
square and no pentagon fraction was detected. Overall, the
nanoparticle with fewer 3WJ motifs (triangle) resulted in a
higher thermostability and resistance in chemical degradation and the change in stability was in large part due to the
stretching of the LAOB.
Toxicity Assay for CpG-RNA Polygons
The modulation effect of triangle, square and pentagon
harboring immunologic adjuvant CpG oligonucleotide is an
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immunological adjuvant popularly used as vaccine adjuvant
or immunotherapy reagent for disease control and treatment
(42). To evaluate whether RNA polygons can enhance the
immunomodulation effect, CpG oligonucleotide was incorporated with each RNA polygon using one-pot self-assembly (FIGS. 10-12). The toxicity assay for the resulting
complexes revealed no toxicity; moreover the RNA polygon-CpG complexes induced cell proliferation during the
incubation period, as compared to the cell only control (FIG.
13).
Measurement of the Release of TNF-Alpha and IL-6
Cytokines
The extracellular immunostimulatory efficacy of RNA
polygons was evaluated by measuring the release of cytokines TNF-a and IL-6 after addition to mouse macrophagelike RAW264.7 cells (FIGS. SA and B), as previously
described ( 56,57). The triangular RNA nanoparticle coupled
with only one CpG exhibited the highest level of cytokine
induction for both TNF -a and IL-6 compared to square and
pentagonal RNA nanoparticles. Increasing the number of
CpG per nanoparticle yielded the opposite effect, as pentagonal RNA nanocarriers showed the highest level of the
induction of both TNF-a and IL-6 presumably due to the
increased local CpG concentration. The results suggest that
the cytokine release by CpG coupled to RNA polygons with
different shapes remarkably increases the immunostimulatory activity compared to CpG alone (FIG. 5). RNA particles
with the size of about 10 nm, such as the triangle, induced
the greatest amount of TNF-a and IL-6. In addition, the
induction of cytokines was highly dependent on the number
of CpG per polygon. With increasing number of CpG per
polygon, a stronger immune response is observed (FIG. SC),
demonstrating an advantage of transiting from triangle to
pentagon that can carry five CpG oligonucleotides.
Enhancement of Modulation Effect in Animal by Immunological Adjuvant Incorporated into RNA Triangle
To examine whether RNA nanoparticles retain their
immunostimulatory activity in vivo, nanoparticles were
administered to CD-1 mice by injection into the tail vein at
2 mg/kg (CpG oligonucleotide per body weight), following
level determination of cytokine TNF-a and IL-6 levels after
3 h post-administration in collected blood seflllll. FIG. SD
shows that free triangle nanoparticles and free CpGs did not
induce any cytokine production, whereas the complex triangle-CpG resulted in elevated levels of both cytokines. The
difference in immunostimulatory activity of triangle-CpG
was estimated to be 10-fold compared to free CpG in vivo.
These data are in agreement with the in vitro stimulation of
murine RAW264.7 cells.
Comparison of Cellular Uptake by Different CpG-RNA
Polygons
Previously, it has been demonstrated that the CpG oligonucleotide can be readily recognized by TLR9 on the
endosomal membrane of macrophages, resulting in cellular
uptake of the CpG adjuvants (58,59). To investigate whether
there is a difference between the efficiency of RNA polygons
binding to the cells, we quantified the cellular uptake of
polygons-CpG using flow cytometry assay (9,10). FIG. 6A
demonstrates the binding of different RNA polygon-CpG to
the RAW264.7 cells in a dose-dependent manner. There was
an increase in binding efficiency from triangle to pentagon
with more CpGs (FIG. 14). Notably, all RNA polygons-CpG
complexes remain intact after 16 h incubation in fetal bovine
seflllll (FBS) indicating robustness of the assembled complex in extracellular environment (FIG. 15). Overall, RNA
polygon-CpG complexes exhibit significantly more binding
efficiency to cells compared to CpG oligonucleotides alone.

This observation was further confirmed by confocal
microscopy images (FIG. 6B) revealing that RNA nanoparticle harboring CpGs are localized in the cytoplasm exclusively and that there are much higher amounts of triangular
nanoparticles inside the cell compared to free CpG, suggesting that RNA nanoparticles could efficiently enhance the
cellular uptake of the CpG adjuvants.
Collectively, both flow cytometry and confocal imaging
demonstrated that all RNA nanoparticles with different
shape and harboring CpGs have much stronger binding and
cellular entry to the macrophage-like RAW 264.7 cells
compared to free CpGs. In addition, cellular uptake was
highly dependent on the number of CpG per polygon. With
the increasing number of CpG per polygon, more efficient
cell entry was observed (FIG. SC), demonstrating the advantage of the transition from triangle to pentagon nanoparticles
that can carry five CpG.
Artificial construction of RNA nanoparticles requires
knowledge of the structural properties of RNA motifs, such
as interhelical or intrahelical distances, X-Y and X-Y-Z
angles, number and orientations of RNA branches in multiway junctions, canonical and non-canonical interactions,
binding sites for proteins, metal ions and small molecules (2,
10, 16, 25, 51, 60). Progression in RNA structural biology
allowed for the analysis of RNA 3D motifs from existing
RNA structures at atomic resolution and various data bases,
including www.pdb.com, RNA multi-way junction (61) and
find RNA motif (62). This study, based on the previously
reported versatile pRNA 3WJ 3D motifs (PDB accession ID:
4KZ2) (10,51), shows that the 3WJ structure can be folded
into desired conformations based on the dynamics of the 60°
LAOC, demonstrating the ability to tune the physical and
structural properties of RNA polygons for a variety of
technological, biological and medicinal needs. This
approach, based on the propagation of the central RNA
strand used to direct the folding of corresponding short or
external strands into planar triangle, square and pentagon
conformations, resulted in the 60°, 90° and 108° bending of
interhelical LAOC of the pRNA 3WJ. This is especially
important for medical applications where one needs to
construct different RNA nano-scaffolds based on a nontoxic
and thermodynamically stable building block. The following
advantages result from this technique: (i) the number and
combination of therapeutic molecules can be tuned to an
RNA-based nano-carrier; (ii) the nano-scaffold has a controllable size and shape and (iii) variable thermodynamic
and RNase resistance properties can be applied depending
on the application of the nano-scaffold.
In addition to the discovery of the unique approach for the
rational design of stable RNA nanoparticles, it has been
demonstrated that each RNA polygon has the potential to
serve as multivalent nanocarriers of vaccine adjuvants, particularly of CpG oligodeoxynucleotides. The designed
RNAs self-assemble into distinct, non-toxic homogeneous
nanoparticles with high chemical, thermal and intracellular
stability. We found that the size and shape of the RNA
nanostructures are important factors for the induction of
immunostimulatory processes in vitro and in animal models
and that there is a correlation between the cytokine induction
and the local CpG concentration effect. The highest level of
secretion of pro-inflanimatory cytokines tumor necrosis factor TNF-a, interleukin (IL)-6 was obtained with the smallest
nanoparticle (triangle-9 nm size) harboring one CpG compared to square (-11 nm) and pentagon (-13 nm). However,
upon increasing the numbers of CpG per RNA nanoparticle
the cytokine induction was affected more by pentagon as the
number or local concentration of CpG is highest in the
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pentagon. This study illustrates the importance of the size
11. Haque, F., Shu, D., Shu, Y., Shlyakhtenko, L., Rychahou,
and shape of RNA nanoparticles for improvement of activity
P., Evers, M. and Guo, P. (2012) Ultrastable synergistic
of CpG based vaccines targeting infectious diseases and
tetravalent RNA nanoparticles for targeting to cancers.
cancer cells, as well as for increasing immune-response by
Nano Today, 7, 245-257.
the innate and adaptive immune systems. The RNA nano- 5 12. Shu, D., Zhang, L., Khisamutdinov, E. and Guo, P.
particles harboring CpGs are safe, effective, versatile and
(2013) Programmable folding of fusion RNA complex
easy to manufacture, offering new solutions to address the
driven by the 3 WJ motif of phi29 motor pRNA. Nucleic
unmet needs in current vaccines and adjuvants. Recent
Acids Res.
findings on the thermodynamically ultra-stable (10,11) and
13. Ponchon, L. and Dardel, F. (2007) Recombinant RNA
10
heat-resistant (18) RNA nanoparticles have expanded the
technology: the tRNA scaffold. Nat. Methods, 4, 571-576.
potential for application of pRNA 3WJ derived nanopar14. Severcan, I., Geary, C., Chworos,A., Voss, N., Jacovetty,
ticles in the fields of biomedical, nanotechnology, or polyE. and Jaeger, L. (2010) A polyhedron made of tRNAs.
mer industries.
Nat. Chem., 2, 772-779.
In FIG. 64, cytokine testing of2'F triangle harboring CpG, 15 15. Nasalean, L., Baudrey, S., Leontis, N. B. and Jaeger, L.
DNA triangle harboring DNA CpG and 2'F triangle harbor(2006) Controlling RNA self-assembly to form filaments.
ing 2'F RNA CpG shows increased TNF-a in cell culture
Nucleic Acids Res., 34, 1381-1392.
supernatant in the 2'F Triangle harboring 2'F RNA CpG
16. Novikova, I. V., Hassan, B. H., Mirzoyan, M. G. and
compared to 2'F triangle harboring DNA CpG and DNA
Leontis, N. B. (2010) Engineering cooperative tecto-RNA
triangle harboring DNA CpG.
complexes having programmable stoichiometries.
20
Throughout this document, various references are menNucleic Acids Res., 39, 2903-2917.
tioned. All such references are incorporated herein by ref17. Ishikawa, J., Fujita, Y., Maeda, Y., Furuta, H. and Ikawa,
Y. (2010) GNRA/receptor interacting modules: versatile
erence, including the references set forth in the following
modular units for natural and artificial RNA architectures.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 93
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 1
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 2
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 2
gggagcgugc aaucauggca acgauagagc auacuuuguu ggcuggac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 3
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

48
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39
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 66
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 4
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uauggc

66

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 5
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 6
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 6
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 7
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 7
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 8
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 8
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 9
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 9
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60
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42
-continued

uaugcgaugc gcuugucaug uguauggc

<210>
<211>
<212>
<213>
<220>
<223>

88

SEQ ID NO 10
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 10
gggagccguc aaucauggca aguguccgcc auacuuuguu guagggca

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 11
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 11
gggacccuac aaucauggca aauaugcgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 12
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 12
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 13
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 13
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggag

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 14
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 14
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 15
LENGTH, 110
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polynucleotide

<400> SEQUENCE, 15
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60
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43

44
-continued

uaugcgaugc gcuugucaug uguauggcgc auauuuguca uguguauggc

<210>
<211>
<212>
<213>
<220>
<223>

110

SEQ ID NO 16
LENGTH, 46
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 16
uccaugacgu uccugacguu uuuuuuacag ucguauugca uuccga

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 17
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 17
tccatgacgt tcctgacgtt ttttttacag tcgtattgca ttccga

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 18
LENGTH, 46
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 18
uccaugacgu uccugacguu uuuuuccaua ccgccauuuc caacua

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 19
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 19
tccatgacgt tcctgacgtt tttttccata ccgccatttc caacta

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 20
LENGTH, 46
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 20
uccaugacgu uccugacguu uuuuuaagca caugcgaugu uuaacu

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 21
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 21

46
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46

45
-continued
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 22
LENGTH, 73
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 22
gguccaugac guuccugacg uuuuuuuggg ccgucaauca uggcaagugu ccgccauacu

60

uuguugcacg ccc

73

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 23
LENGTH, 73
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 23
gguccaugac guuccugacg uuuuuuuggg cgugcaauca uggcaacgau agagcauacu

60

uuguuggcug gee

73

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 24
LENGTH, 73
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 24
gguccaugac guuccugacg uuuuuuuggc cagccaauca uggcaauaua cacgcauacu

60

uuguugacgg ccc

73

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 25
LENGTH, 63
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 25
taatacgact cactatatcc atgacgttcc tgacgttttt tttacagtcg tattgcattc

60

cga

63

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 26
LENGTH, 38
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 26
taatacgact cactatatcc atgacgttcc tgacgttt

<210> SEQ ID NO 27
<211> LENGTH, 37
<212> TYPE, DNA

38
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47

48
-continued

<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer
<400> SEQUENCE, 27
tcggaatgca atacgactgt aaaaaaaacg tcaggaa

<210>
<211>
<212>
<213>
<220>
<223>

37

SEQ ID NO 28
LENGTH, 63
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 28
taatacgact cactatatcc atgacgttcc tgacgttttt ttccataccg ccatttccaa

60

eta

63

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 29
LENGTH, 38
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 29
taatacgact cactatatcc atgacgttcc tgacgttt

<210>
<211>
<212>
<213>
<220>
<223>

38

SEQ ID NO 30
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 30
tagttggaaa tggcggtatg gaaaaaaacg tcaggaa

<210>
<211>
<212>
<213>
<220>
<223>

37

SEQ ID NO 31
LENGTH, 63
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 31
taatacgact cactatatcc atgacgttcc tgacgttttt ttaagcacat gcgatgttta

60

act

63

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 32
LENGTH, 38
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 32
taatacgact cactatatcc atgacgttcc tgacgttt

38
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50

49
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 33
LENGTH, 37
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 33
agttaaacat cgcatgtgct taaaaaaacg tcaggaa

<210>
<211>
<212>
<213>
<220>
<223>

37

SEQ ID NO 34
LENGTH, 14
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 34
uugucaugug uaug

<210>
<211>
<212>
<213>
<220>
<223>

14

SEQ ID NO 35
LENGTH, 13
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 35
cauacuuugu uga

<210>
<211>
<212>
<213>
<220>
<223>

13

SEQ ID NO 36
LENGTH, 13
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 36
ucaaucaugg caa

<210>
<211>
<212>
<213>
<220>
<223>

13

SEQ ID NO 37
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 37
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 38
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 38
gggagcgugc aaucauggca acgauagagc auacuuuguu ggcuggac

<210> SEQ ID NO 39

48
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52

51
-continued
<211>
<212>
<213>
<220>
<223>

LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 39
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 40
LENGTH, 66
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 40
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uauggc

66

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 41
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 41
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 42
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 42
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 43
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 43
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 44
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 44
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

48
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54

53
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 45
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 45
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uaugcgaugc gcuugucaug uguauggc

88

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 46
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 46
gggagccguc aaucauggca aguguccgcc auacuuuguu guagggca

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 47
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 47
gggacccuac aaucauggca aauaugcgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 48
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 48
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 49
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 49
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggag

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 50
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 50
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

48
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56
-continued

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 51
LENGTH, 110
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polynucleotide

<400> SEQUENCE, 51
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug
uaugcgaugc gcuugucaug uguauggcgc auauuuguca uguguauggc

<210>
<211>
<212>
<213>
<220>
<223>

60

110

SEQ ID NO 52
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 52
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 53
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 53
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcucuc ucggaaugca

60

auacgacugu a

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 54
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 54
tccatgacgt tcctgacgtt ttttttacag tcgtattgca ttccga

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 55
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 55
gggagcgugc aaucauggca acgauagagc auacuuuguu ggcuggucuc uaguuggaaa

60

uggcgguaug g

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 56
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
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58

57
-continued
<400> SEQUENCE, 56
tccatgacgt tcctgacgtt tttttccata ccgccatttc caacta

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 57
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 57
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcucuc aguuaaacau

60

cgcaugugcu u

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 58
LENGTH, 66
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 58
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uauggc

66

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 59
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 59
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 60
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 60
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcucuc ucggaaugca

60

auacgacugu a

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 61
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 61
tccatgacgt tcctgacgtt ttttttacag tcgtattgca ttccga

<210> SEQ ID NO 62
<211> LENGTH, 71

46
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59

60
-continued

<212>
<213>
<220>
<223>

TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 62
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccucuc auugaucuau

60

gaucguacga u

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 63
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 63
tccatgacgt tcctgacgtt tttttatcgt acgatcatag atcaat

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 64
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 64
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggucuc uaguuggaaa

60

uggcgguaug g

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 65
LENGTH, 117
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polynucleotide
<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic polynucleotide
<400> SEQUENCE, 65
tccatgacgt tcctgacgtt tttttccata ccgccatttc caactaggga ccagccaauc
auggcaauau acacgcauac uuuguugacg gcucucaguu aaacaucgca ugugcuu

<210>
<211>
<212>
<213>
<220>
<223>

60

117

SEQ ID NO 66
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 66
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uaugcgaugc gcuugucaug uguauggc

88

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 67
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
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61

62
-continued

<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<400> SEQUENCE, 67
tccatgacgt tcctgacgtt tttttaagca catgcgatgt ttaact

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 68
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 68
gggagccguc aaucauggca aguguccgcc auacuuuguu guagggucuc auguuaagua

60

acgucuagaa u

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 69
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 69
tccatgacgt tcctgacgtt tttttattct agacgttact taacat

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 70
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 70
gggacccuac aaucauggca aauaugcgcc auacuuuguu gcacgcucuc gaaagcuugu

60

agcuauaguu a

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 71
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 71
tccatgacgt tcctgacgtt ttttttaact atagctacaa gctttc

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 72
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 72
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccucuc auugaucuau

60

gaucguacga u

71
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64

63
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 73
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 73
tccatgacgt tcctgacgtt tttttatcgt acgatcatag atcaat

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 74
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 74
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggucuc uaguuggaaa

60

uggcgguaug g

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 75
LENGTH, 46
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 75
46

tccatgacgt tcctgacgtt tttttccata ccgccatttc caacta

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 76
LENGTH, 71
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 76
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcucuc aguuaaacau

60

cgcaugugcu u

71

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 77
LENGTH, 110
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polynucleotide

<400> SEQUENCE, 77
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug
uaugcgaugc gcuugucaug uguauggcgc auauuuguca uguguauggc

<210>
<211>
<212>
<213>
<220>
<223>

60

110

SEQ ID NO 78
LENGTH, 64
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
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65

66
-continued

<400> SEQUENCE, 78
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uaug

64

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 79
LENGTH, 27
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 79
gggccgucaa ucauggcaag uguccgc

<210>
<211>
<212>
<213>
<220>
<223>

27

SEQ ID NO 80
LENGTH, 46
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 80
ggccagccaa ucauggcaau auacacgcau acuuuguuga cggccc

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 81
LENGTH, 46
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 81
gggcgugcaa ucauggcaac gauagagcau acuuuguugg cuggcc

<210>
<211>
<212>
<213>
<220>
<223>

46

SEQ ID NO 82
LENGTH, 19
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 82
cauacuuugu ugcacgccc

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 83
LENGTH, 67
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 83
gggccgucaa ucauggcaag uguccgccau acuuuguugc acgcccucgg aaugcaauac

60

gacugua

67

<210>
<211>
<212>
<213>
<220>

SEQ ID NO 84
LENGTH, 67
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
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-continued
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 84
gggcgugcaa ucauggcaac gauagagcau acuuuguugg cuggccuagu uggaaauggc

60

gguaugg

67

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 85
LENGTH, 67
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 85
ggccagccaa ucauggcaau auacacgcau acuuuguuga cggcccaguu aaacaucgca

60

ugugcuu

67

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 86
LENGTH, 43
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic oligonucleotide

<400> SEQUENCE, 86
tccatgacgt tcctgacgtt tttttuugcc auguguaugu ggg

<210>
<211>
<212>
<213>
<220>
<223>

43

SEQ ID NO 87
LENGTH, 16
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 87
ggaucaauca uggcaa

<210>
<211>
<212>
<213>
<220>
<223>

16

SEQ ID NO 88
LENGTH, 45
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic oligonucleotide

<400> SEQUENCE, 88
tccatgacgt tcctgacgtt tttttcccac auacuuuguu gaucc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 89
LENGTH, 64
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 89

45
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69

70
-continued

ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uaug

64

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 90
LENGTH, 54
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 90
gguccaugac guuccugacg uuuuuuuggg ccgucaauca uggcaagugu ccgc

<210>
<211>
<212>
<213>
<220>
<223>

54

SEQ ID NO 91
LENGTH, 73
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 91
gguccaugac guuccugacg uuuuuuuggc cagccaauca uggcaauaua cacgcauacu

60

uuguugacgg ccc

73

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 92
LENGTH, 73
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 92
gguccaugac guuccugacg uuuuuuuggg cgugcaauca uggcaacgau agagcauacu

60

uuguuggcug gee

73

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 93
LENGTH, 19
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 93
19

cauacuuugu ugcacgccc

What is claimed is:

3. The nanostructure of claim 1, wherein the internal

1. An artificial RNA nanostructure, comprising multiple 55 strands and external strands assembled to form a triangle
nanostructure, a square nanostructure, or a polygon nano-

external RNA stands and an internal RNA strand, wherein
the internal strand and the external strands assemble to form
a polygon nanostructure, wherein a pRNA three-way junction (3 WJ) motif comprises each vertex of the nano structure;
and wherein the nanostructure comprises one or more of the
sequences having at least 90% identity to SEQ ID NOs 1-4,
5-9 or 10-15.
2. The nanostructure of claim 1, wherein the multiple
external RNA strands comprises three, four, or five external
strands of RNA.

60

65

structure.
4. The nanostructure of claim 1, wherein the nanostructure comprises a stretched intrahelical angle between HI and
H2.
5. The nanostructure of claim 1, further comprising one or
more immunostimulatory motifs or adjuvants.
6. The nanostructure of claim 5, wherein the one or more
immunostimulatory motifs or adjuvants are selected from
selected from one or more immunostimulatory RN As
(isRNA) or CpG oligodeoxyribonucleotide (CpG) motifs,
wherein the one or more CpG motifs have a sequence at least
90% identical to SEQ ID NO: 16.

US 10,378,018 B2
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7. The nanostructure of claim 1, further comprising at

least one adjuvant, antigen, and/or targeting ligand.
8. The nanostructure of claim 1, wherein the nanostructure induces an immune response.
9. The nanostructure of claim 8, wherein the immune
response increases cytokine at least ten fold as compared to
the adjuvant, the antigen, and/or the targeting ligand provided independently of the RNA nanostructure.
10. The nanostructure of claim 7, wherein the antigen is
derived from a bacteria, virus, or cell.
11. The nanostructure of claim 7, wherein the antigen
binds to a neutralizing antibody or an inhibitory antibody.
12. The nanostructure of claim 7, wherein the antigen is
selected from B-cell epitope, T-cell epitope, T-helper
epitope, epitopes derived from PG120, gp4leptopes, glycans, peptides, T-helper peptides, and streptavidin.
13. The nanostructure of claim 7, wherein the targeting
ligand is selected from an aptamer, a cell surface marker,
folate, siRNA and shRNA.

14. The nanostructure of claim 7, wherein the targeting
ligand targets B cells, T cells, dendritic cells, macrophages,
and/or cancer cells.
5

10

15

15. A composition, comprising: (a) an RNA nanostructure, wherein the RNA nanostructure is selected from RNA
nano structure of claim 1, RNA three-way junction, and RNA
four-way junction, and wherein the RNA nanostructure
contains a stretched intrahelical angle between HI and H2;
and (b) an adjuvant, an antigen, and/or a targeting ligand.
16. The composition of claim 15, wherein the adjuvant is
a composition comprising: (a) an RNA-oligonucleotide,
wherein the RNA-oligonucleotide comprises singlestranded or double stranded oligonucleotide, and wherein
RNA-oligonucleotide is about 8-50 bases in length; and (b)
an immunostimulatory motif, wherein the immunostimulatory motif is conjugated to the RNA-oligonucleotide.

* * * * *

